Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

23
results for

"Ascites"

Article category

Keywords

Publication year

"Ascites"

Editorial

Liver fibrosis, cirrhosis, and portal hypertension

Citations

Citations to this article as recorded by  Crossref logo
  • TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with deco
    Anja Tiede, Benjamin Maasoumy
    Clinical and Molecular Hepatology.2025; 31(2): e176.     CrossRef
  • Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrh
    Georg Semmler, Lorenz Balcar, Mattias Mandorfer
    Clinical and Molecular Hepatology.2025; 31(2): e224.     CrossRef
  • Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
    Lucie Simonis, Lorenz Balcar, Anna Schedlbauer, Marta Tonon, Nikolaj Torp, Valeria Santori, Katharina Stopfer, Jan Embacher, Christian Sebesta, Leonie Hafner, Benedikt Silvester Hofer, Nina Dominik, Georg Kramer, Paul Thöne, Michael Trauner, Aleksander Kr
    Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1202.     CrossRef
  • Systemic inflammatory indexes as predictors of 18-month mortality among cirrhotic patients receiving transjugular intrahepatic portosystemic shunt
    Jie Cheng, Xiaobing Wang, Lihua Zhou, Xiaojia Chen, Nuer Tang, Feng Zhou, Feng Ding, Yuan Yang, Jun Lin, Liping Chen
    Annals of Medicine.2025;[Epub]     CrossRef
  • 5,809 View
  • 60 Download
  • 5 Web of Science
  • Crossref

Correspondence

Viral hepatitis

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
Clin Mol Hepatol 2023;29(1):188-190.
Published online November 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0408

Citations

Citations to this article as recorded by  Crossref logo
  • Prevention of Decompensation in Compensated Cirrhosis: Non-Selective Beta-Blockers for Everyone?
    Sanchit Sharma, Dhiraj Tripathi
    EMJ Hepatology.2024; : 74.     CrossRef
  • How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1610.     CrossRef
  • Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis
    Huapeng Lin, Jimmy Che‐To Lai, Grace Lai‐Hung Wong, Adèle Delamarre, Sang Hoon Ahn, Guanlin Li, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Sherlot Juan Song, Henry Lik‐Yuen Chan, Vincent Wai‐Sun Wong, Victor de Lédinghen, Seung Up Kim, Terry Cheuk‐Fun
    Alimentary Pharmacology & Therapeutics.2023; 58(9): 920.     CrossRef
  • 6,746 View
  • 74 Download
  • 2 Web of Science
  • Crossref

Reviews

Liver fibrosis, cirrhosis, and portal hypertension

Management of refractory ascites
Florence Wong
Clin Mol Hepatol 2023;29(1):16-32.
Published online June 9, 2022
DOI: https://doi.org/10.3350/cmh.2022.0104
The development of refractory ascites in approximately 10% of patients with decompensated cirrhosis heralds the progression to a more advanced stage of cirrhosis. Its pathogenesis is related to significant hemodynamic changes, initiated by portal hypertension, but ultimately leading to renal hypoperfusion and avid sodium retention. Inflammation can also contribute to the pathogenesis of refractory ascites by causing portal microthrombi, perpetuating the portal hypertension. Many complications accompany the development of refractory ascites, but renal dysfunction is most common. Management starts with continuation of sodium restriction, which needs frequent reviews for adherence; and regular large volume paracentesis of 5 L or more with albumin infusions to prevent the development of paracentesisinduced circulatory dysfunction. Albumin infusions independent of paracentesis may have a role in the management of these patients. The insertion of a covered, smaller diameter, transjugular intrahepatic porto-systemic stent shunt (TIPS) in the appropriate patients with reasonable liver reserve can bring about improvement in quality of life and improved survival after ascites clearance. Devices such as an automated low-flow ascites pump may be available in the future for ascites treatment. Patients with refractory ascites should be referred for liver transplant, as their prognosis is poor. In patients with refractory ascites and concomitant chronic kidney disease of more than stage 3b, assessment should be referred for dual liver-kidney transplants. In patients with very advanced cirrhosis not suitable for any definitive treatment for ascites control, palliative care should be involved to improve the quality of life of these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Outcomes following nurse-led day-case paracentesis
    Mahir Yousuff, Pramudi Wijayasiri, Renee Ma, Rabiat Umar, Ripak Purbe, Nicola J. Monahan, Helen L. Garrity, Beverley J. Aram, Naaventhan Palaniyappan, Emilie Wilkes, Aloysious D. Aravinthan
    Clinical Medicine.2026; 26(1): 100538.     CrossRef
  • Integrated analysis of gut microbiota structure and metabolic function in patients with cirrhosis and refractory ascites
    Dianyan Chen, Sandu Liu, Ka Zhang, Ke Pan, Linsu Zhang, Deyun Shu, Jin Zhang, Dingyao Ren
    Biomedical Reports.2026; 24(2): 1.     CrossRef
  • Proximal splenic artery embolization for treatment of refractory ascites, a single‐center experience
    Abdul Rehman Mustafa, Raneem Atta, Russell P. Goodman, Vincent Wu, Zubin Irani, Omar Zurkiya, Emily D. Bethea, Kei Yamada, Eric P. Wehrenberg‐Klee
    Hepatology Research.2025; 55(2): 219.     CrossRef
  • Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and Ascites
    Florence Wong, K. Rajender Reddy, Puneeta Tandon, Jennifer C. Lai, Guadalupe Garcia-Tsao, Jacqueline G. O'Leary, Scott W. Biggins, Hugo E. Vargas, Leroy Thacker, Patrick S. Kamath, Jasmohan S. Bajaj
    American Journal of Gastroenterology.2025; 120(8): 1791.     CrossRef
  • Midodrine and Weekly Albumin Therapy in Patients With Cirrhosis and Diuretic Intractable or Recurrent Ascites: A Case-Control Study
    Gourav J Borah, Gaurav Pande, Sayan Malakar, S Rakesh Kumar, Rajanikant R Yadav, Samir Mohindra
    Cureus.2025;[Epub]     CrossRef
  • The use of virtual reality-assisted interventions on psychological well-being and treatment adherence among kidney transplant recipients: A randomized controlled study
    Chao Zhong, Lin Yao, Lanlan Chen, Xiaofen Wang, Xiaohui Zhu, Yihong Wen, Lei Deng, Jiafu Chen, Jialiang Hui, Lisha Shi, Lijuan You
    Acta Psychologica.2025; 253: 104700.     CrossRef
  • Comparison of clinical outcomes in patients with refractory ascites treated with either TIPS, tunneled peritoneal catheter, or ascites pump
    Sarah L. Schütte, Anja Tiede, Jim B. Mauz, Hannah Rieland, Martin Kabelitz, Robin Iker, Nicolas Richter, Bernhard Meyer, Benjamin Heidrich, Heiner Wedemeyer, Benjamin Maasoumy, Tammo L. Tergast
    Hepatology Communications.2025;[Epub]     CrossRef
  • Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study
    Martin A. Kabelitz, Lukas Hartl, Golda Schaub, Anja Tiede, Hannah Rieland, Andrea Kornfehl, Peter Hübener, Mathias Jachs, Jan Hinrichs, Sarah L. Schütte, Christoph Riedel, Jim B. Mauz, Tammo L. Tergast, Bernhard C. Meyer, Peter Bannas, Julia Kappel, Heine
    Hepatology.2025; 82(5): 1172.     CrossRef
  • The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites
    Florence Wong, Hugo E. Vagas, K. Rajender Reddy, Mangesh R. Pagadala, Christine Pocha, Vinay Sundaram, Jasmohan S. Bajaj, Eran Shlomovitz, Emily Bendel, Jeroen Capel, Patrick S. Kamath
    American Journal of Gastroenterology.2025; 120(10): 2291.     CrossRef
  • Comparison of clinical outcomes of transjugular intrahepatic portosystemic shunt for refractory ascites and recurrent nonrefractory ascites
    Shi-Hua Luo, Hui-Fang Zhang, Wei Liu, Jian-Guo Chu, Jian-Yong Chen
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report
    Keisuke Baba, Tomoki Tanie, Yasuo Matsubara, Yoshihiro Hirata, Hiroaki Ikematsu, Narikazu Boku
    Case Reports in Oncology.2025; 18(1): 286.     CrossRef
  • Pharmacological Treatment of Ascites: Challenges and Controversies
    Jimmy Che-To Lai, Junlong Dai, Lilian Yan Liang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
    Pharmaceuticals.2025; 18(3): 339.     CrossRef
  • A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study
    Lanyue Pan, Chunmei Wu, Ping Li, Jiaquan Huang, Yizhi Wu, Guo Li, Aysegul Taylan Ozkan
    PLOS Neglected Tropical Diseases.2025; 19(5): e0013134.     CrossRef
  • Investigation of bending angle algorithm and path planning for puncture needles in transjugular intrahepatic portosystemic shunt
    Qinmei Liao, Bing Li, Xihao Hu, Xiaoyun Huang, Jiacheng Guo, Yuanzhong Zhu, Wenjing He
    BioMedical Engineering OnLine.2025;[Epub]     CrossRef
  • Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Cirrhosis Taking Diuretics—A Promising Step Toward Fewer Serious Liver Events
    Mohamed I. Elsaid
    JAMA Network Open.2025; 8(6): e2518478.     CrossRef
  • Jabor A., Březina A.: Analysis od less common body fluids: Part 2 - peritoneal fluid and ascites
    A Jabor, A Březina
    Klinická biochemie a metabolismus.2025; 33(2): 34.     CrossRef
  • TIPS in Patients With Refractory Ascites: Review of Literature and Current Recommendations
    Matthew Abad-Santos, James Jeffries, Charles Hua, Guy E. Johnson
    Techniques in Vascular and Interventional Radiology.2025; : 101057.     CrossRef
  • Impacts of salt restriction on nutritional status, sarcopenia, and mortality of cirrhotic patients with ascites
    Maha Elsabaawy, Mohammed Ragab, Madiha Naguib, Eman Kamal, Maymona Al-Khalifa, Khaled Gamil, Marwa Elfayoumy
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
    Jasmohan S. Bajaj, Ethan M. Weinberg, K. Rajender Reddy, Andrew P. Keaveny, Michael K. Porayko, David Koch, Paul J. Thuluvath, Douglas A. Simonetto, Paolo Angeli, Sujit V. Janardhan, Eric S. Orman, Jeffrey Zhang, Susan Clausen, Elisa Dauphinée, Joseph M.
    Liver Transplantation.2025; 31(10): 1202.     CrossRef
  • Refractory Ascites in Patients With Cirrhosis
    Madhumita Premkumar
    JGH Open.2025;[Epub]     CrossRef
  • Future research direction of portal hypertension based on Baveno VII
    Xuefeng Luo, Guangchuan Wang, Li Yang, Virginia Hernandez-Gea
    Chinese Medical Journal.2025; 138(18): 2268.     CrossRef
  • New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target
    Yunqi Xing, Yanghao Ou, Yujie Wang, Luming Hou, Junfeng Zhu
    Biochemical Pharmacology.2025; 242: 117284.     CrossRef
  • Managing Ascites and Kidney Dysfunction in Decompensated Advanced Chronic Liver Disease: From “One Size Fits All” to a Multidisciplinary-Tailored Approach
    Mario Romeo, Carmine Napolitano, Paolo Vaia, Fiammetta Di Nardo, Silvio Borrelli, Carlo Garofalo, Luca De Nicola, Alessandro Federico, Marcello Dallio
    Livers.2025; 5(3): 46.     CrossRef
  • Predicting severe renal dysfunction in alcohol-associated cirrhosis: Comparative performance of liver function scores and machine learning models
    Julian Müller-Kühnle, Moritz Schanz, Severin Schricker, Christian Benignus, Julia Todoroff, Jörg Latus, Wolfram Zoller, Dominik Marschner, Zhaoqing Du
    PLOS One.2025; 20(9): e0332840.     CrossRef
  • Decompensated cirrhosis but low MELD—Should we wait or refer for liver transplantation?
    Noreen Singh, Yu Jun Wong, Patrizia Burra, Nazia Selzner, Aldo J. Montano-Loza
    Liver Transplantation.2025; 31(11): 1423.     CrossRef
  • Management of intractable ascites in cirrhosis: a review article
    I. Dewa Ayu Made Dian Lestari, Ketut Suryana
    International Journal of Advances in Medicine.2025; 13(1): 56.     CrossRef
  • Acute kidney injury after TIPS in decompensated cirrhosis patients: a retrospective cohort study
    Meng Jia, Yi-Dan Guo, Peng-Peng Ye, Xiao-Ling Zhou, Yang Luo
    BMC Nephrology.2025;[Epub]     CrossRef
  • Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa
    Mark W Sonderup, Patrick S Kamath, Yaw A Awuku, Hailemichael Desalegn, Neliswa Gogela, Leolin Katsidzira, Christian Tzeuton, Bilal Bobat, Chris Kassianides, C Wendy Spearman
    The Lancet Gastroenterology & Hepatology.2024; 9(2): 170.     CrossRef
  • Recent developments in the management of ascites in cirrhosis
    Tian Lan, Ming Chen, Chengwei Tang, Pierre Deltenre
    United European Gastroenterology Journal.2024; 12(2): 261.     CrossRef
  • A new strategy for the treatment of refractory ascites in patients with hepatitis B-related liver cirrhosis
    Wenjing Xu, Gang Wang
    Asian Journal of Surgery.2024; 47(6): 2761.     CrossRef
  • Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis
    Shingo Koyama, Asako Nogami, Masato Yoneda, Shihyao Cheng, Yuya Koike, Yuka Takeuchi, Michihiro Iwaki, Takashi Kobayashi, Satoru Saito, Daisuke Utsunomiya, Atsushi Nakajima
    Tomography.2024; 10(4): 471.     CrossRef
  • Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
    Danielle Adebayo, Florence Wong
    Alimentary Pharmacology & Therapeutics.2024; 59(10): 1196.     CrossRef
  • Treatment of portal hypertension complicated by variceal bleeding
    M.I. Tutchenko, D.V. Rudyk, І.V. Klyuzko, M.S. Besedinskyi, S.L. Chub, О.А. Sirenko
    EMERGENCY MEDICINE.2024; 20(3): 180.     CrossRef
  • External treatment of refractory ascites induced by liver cirrhosis using traditional Chinese medicine
    Xuerong Wang, Xiaoqin Zeng, Gang Wang
    Asian Journal of Surgery.2024; 47(10): 4429.     CrossRef
  • Shunt dysfunction and mortality after transjugular intrahepatic portosystemic shunt (TIPS) in patients with portal hypertension
    Laura Büttner, Lisa Pick, Martin Jonczyk, Uli Fehrenbach, Federico Collettini, Timo Alexander Auer, Dirk Schnapauff, Maximilian De Bucourt, Gero Wieners, Bernhard Gebauer, Annette Aigner, Georg Böning
    Insights into Imaging.2024;[Epub]     CrossRef
  • Advancements in ascites management: a comprehensive narrative review of the Alfa Pump system
    Muhammad Asim, Nabiha Naqvi, Vikash Kumar Karmani, Aima Tahir, Umm E. Salma Shabbar Banatwala, Shahzeb Rehman, Minha Aslam, Aleena Majeed, Farhan Khan
    Egyptian Liver Journal.2024;[Epub]     CrossRef
  • Drainage of ascites in cirrhosis
    Jia-Xing Yang, Yue-Ming Peng, Hao-Tian Zeng, Xi-Min Lin, Zheng-Lei Xu
    World Journal of Hepatology.2024; 16(9): 1245.     CrossRef
  • Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide
    Adonis A Protopapas, Alexandra Tsankof, Ioanna Papagiouvanni, Georgia Kaiafa, Lemonia Skoura, Christos Savopoulos, Ioannis Goulis
    World Journal of Hepatology.2024; 16(12): 1377.     CrossRef
  • A safe and effective treatment for refractory malignant ascites: the use of pigtail catheters
    Akif Doğan, Ömer Aydıner
    Polish Journal of Radiology.2024; 89: 561.     CrossRef
  • Daily Low-Volume Paracentesis and Clinical Complications in Patients With Refractory Ascites
    Tammo L. Tergast, Marie Griemsmann, Lena Stockhoff, Kerstin Port, Benjamin Heidrich, Markus Cornberg, Heiner Wedemeyer, Henrike Lenzen, Nicolas Richter, Elmar Jaeckel, Benjamin Maasoumy
    JAMA Network Open.2023; 6(7): e2322048.     CrossRef
  • Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversies
    Yong He, Lu Chai, Han Chen, Xing-Shun Qi
    World Chinese Journal of Digestology.2023; 31(17): 705.     CrossRef
  • Evidence-based hyponatremia management in liver disease
    Ji Young Ryu, Seon Ha Baek, Sejoong Kim
    Clinical and Molecular Hepatology.2023; 29(4): 924.     CrossRef
  • Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism
    Rahul Arya, Ramesh Kumar, Tarun Kumar, Sudhir Kumar, Utpal Anand, Rajeev Nayan Priyadarshi, Tanmoy Maji
    World Journal of Hepatology.2023; 15(10): 1140.     CrossRef
  • Pulmonary Complications in Patients with Liver Cirrhosis
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    The Korean Journal of Gastroenterology.2023; 82(5): 213.     CrossRef
  • Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Hepatic Encephalopathy—A Review of the Past Decade’s Literature Focusing on Incidence, Risk Factors, and Prophylaxis
    Karina Holm Friis, Karen Louise Thomsen, Wim Laleman, Sara Montagnese, Hendrik Vilstrup, Mette Munk Lauridsen
    Journal of Clinical Medicine.2023; 13(1): 14.     CrossRef
  • 19,471 View
  • 1,112 Download
  • 43 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

β-blockers in advanced cirrhosis: More friend than enemy
Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
Clin Mol Hepatol 2021;27(3):425-436.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0234
Nonselective beta-adrenergic blocker (NSBB) therapy for the prevention of initial and recurrent gastrointestinal bleeding in cirrhotic patients with gastroesophageal varices has been used for the past four decades. NSBB therapy is considered the cornerstone of treatment for varices, and has become the standard of care. However, a 2010 study from the group that pioneered β-blocker therapy suggested a detrimental effect of NSBBs in decompensated cirrhosis, especially in patients with refractory ascites. Since then, numerous additional studies have incompletely resolved whether NSBBs are deleterious, although more recent evidence weighs against a harmful effect. The possibility of a “therapeutic window” has also been raised. We aimed to review the literature to analyze the pros and cons of using NSBBs in patients with cirrhosis, not only with respect to bleeding or mortality but also to other potential benefits and risks. β-blockers are highly effective in preventing first bleeding and recurrent bleeding. Furthermore, NSBBs improve congestion/ischemia of the gut mucosa, decrease intestinal permeability, and therefore indirectly alleviate systemic inflammation. β-blockers shorten the electrocardiographic prolonged QTc interval and may also decrease the incidence of hepatocellular carcinoma. On the other hand, the possibility of deleterious effects in cirrhosis has not been completely eliminated. NSBBs may be associated with an increased risk of portal vein thrombosis, although this could be correlational artifact. Overall, we conclude that β-blockers in cirrhosis are much more of a friend than enemy.

Citations

Citations to this article as recorded by  Crossref logo
  • Potential therapies for acute‐on‐chronic liver failure
    Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail
    Liver International.2025;[Epub]     CrossRef
  • Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis
    Zhiqian Liu, Xiying Yang, Haitao Jiang, Rui Xie, Hong Wang
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(4): 102553.     CrossRef
  • Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era
    Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran
    Journal of Clinical Medicine.2025; 14(17): 5993.     CrossRef
  • Principles of Non-selective Beta-blocker Usage for Cirrhosis-associated Complications
    Daisy K. Maclaine, Kosha J. Mehta
    SN Comprehensive Clinical Medicine.2025;[Epub]     CrossRef
  • Cardiomyopathy in cirrhosis: From pathophysiology to clinical care
    Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee
    JHEP Reports.2024; 6(1): 100911.     CrossRef
  • Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities
    Hongqun Liu, Daegon Ryu, Sangyoun Hwang, Samuel S. Lee
    International Journal of Molecular Sciences.2024; 25(11): 5849.     CrossRef
  • Novel approaches in the medical management of compensated cirrhosis
    Antonio Moreno-Loro, Álvaro Giráldez, Fernando Jiménez, Ignacio López-Bueno, Alberto Pérez-Ramírez, Manuel Romero-Gómez
    Expert Review of Gastroenterology & Hepatology.2024; 18(6): 239.     CrossRef
  • Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report)
    M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko
    GASTROENTEROLOGY.2024; 58(2): 151.     CrossRef
  • Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein
    Nicola E. Owen, Thomas L. Williams, Janet J. Maguire, Rhoda E. Kuc, Emma E. Davenport, Anthony P. Davenport
    Bioscience Reports.2024;[Epub]     CrossRef
  • The effect of propranolol on gastrointestinal motility and permeability in patients with cirrhosis and significant portal hypertension
    Elias Xirouchakis, Hariklia Kranidioti, Emilia Hadziyanni, Anastasia Kourikou, Christos Reppas, Maria Vertzoni, Nikolaos Papadopoulos, Melanie Deutsch, George Papatheodoridis, Spilios Manolakopoulos
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension
    Bert Vandenberk, Mario H. Altieri, Hongqun Liu, Satish R. Raj, Samuel S. Lee
    Alimentary Pharmacology & Therapeutics.2023; 57(3): 290.     CrossRef
  • Non-invasive tests-based risk stratification: Baveno VII and beyond
    Georg Semmler, Mathias Jachs, Mattias Mandorfer
    Clinical and Molecular Hepatology.2023; 29(1): 105.     CrossRef
  • Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
    Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
    Clinical and Molecular Hepatology.2023; 29(1): 188.     CrossRef
  • Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1372.     CrossRef
  • Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy
    Sang Youn Hwang, Hongqun Liu, Samuel S. Lee
    Biomedicines.2023; 11(7): 1895.     CrossRef
  • How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
    Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia
    Journal of Gastroenterology and Hepatology.2023; 38(9): 1610.     CrossRef
  • Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy
    Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee
    Pharmaceuticals.2023; 16(7): 978.     CrossRef
  • Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
    Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Portal vein thrombosis in cirrhosis: exploring the uncharted waters
    P Anirvan
    Journal of Gastroenterology and Hepatology.2023; 38(10): 1855.     CrossRef
  • MicroRNAs as critical regulators in liver fibrosis
    Xiaolin Wang, Qiuhong Zai, Yong He, Qing Xie
    Portal Hypertension & Cirrhosis.2023; 2(3): 144.     CrossRef
  • The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status
    Josip Stojic, Michał Kukla, Ivica Grgurevic
    Diagnostics.2023; 13(18): 2960.     CrossRef
  • Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis
    Mason Lai, Cynthia Fenton, Jin Ge, Jessica Rubin, Jennifer C. Lai, Giuseppe Cullaro
    Hepatology Communications.2023;[Epub]     CrossRef
  • Hepatorenal syndrome: Current concepts and future perspectives
    Chan-Young Jung, Jai Won Chang
    Clinical and Molecular Hepatology.2023; 29(4): 891.     CrossRef
  • In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs
    Luke D. Tyson, Stephen Atkinson, Robert W. Hunter, Michael Allison, Andrew Austin, James W. Dear, Ewan Forrest, Tong Liu, Emma Lord, Steven Masson, Joao Nunes, Paul Richardson, Stephen D. Ryder, Mark Wright, Mark Thursz, Nikhil Vergis
    Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1217.     CrossRef
  • Gut liver brain axis in diseases: the implications for therapeutic interventions
    Mengyao Yan, Shuli Man, Benyue Sun, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites
    Jim Höppner, Sandra Krohn, Ellen H. A. van den Munckhof, René Kallies, Adam Herber, Katharina Zeller, Jan Tünnemann, Madlen Matz-Soja, Antonis Chatzinotas, Stephan Böhm, Albrecht Hoffmeister, Thomas Berg, Cornelius Engelmann
    Scientific Reports.2023;[Epub]     CrossRef
  • Current knowledge about biomarkers of acute kidney injury in liver cirrhosis
    Han Ah Lee, Yeon Seok Seo
    Clinical and Molecular Hepatology.2022; 28(1): 31.     CrossRef
  • Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy
    Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee
    Frontiers in Network Physiology.2022;[Epub]     CrossRef
  • Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
    Hankil Lee, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2154.     CrossRef
  • Prolonged QT Interval in Cirrhosis: Twisting Time?
    William Lee, Bert Vandenberk, Satish R. Raj, Samuel S. Lee
    Gut and Liver.2022; 16(6): 849.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • Advances in cirrhotic cardiomyopathy
    Hongqun Liu, Ki Tae Yoon, Jing Zhang, Samuel S. Lee
    Current Opinion in Gastroenterology.2021; 37(3): 187.     CrossRef
  • 12,228 View
  • 312 Download
  • 34 Web of Science
  • Crossref

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients
Priyanka Jain, Saggere Muralikrishna Shasthry, Ashok Kumar Choudhury, Rakhi Maiwall, Guresh Kumar, Ankit Bharadwaj, Vinod Arora, Rajan Vijayaraghavan, Ankur Jindal, Manoj Kumar Sharma, Vikram Bhatia, Shiv Kumar Sarin
Clin Mol Hepatol 2021;27(1):175-185.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0068
Background/Aims
Liver cirrhosis is an important cause of morbidity and mortality globally. Every episode of decompensation and hospitalization reduces survival. We studied the clinical profile and long-term outcomes comparing alcohol-related cirrhosis (ALC) and non-ALC.

Methods
Cirrhosis patients at index hospitalisation (from January 2010 to June 2017), with ≥1 year follow-up were included.

Results
Five thousand and one hundred thirty-eight cirrhosis patients (age, 49.8±14.6 years; male, 79.5%; alcohol, 39.5%; Child-A:B:C, 11.7%:41.6%:46.8%) from their index hospitalization were analysed. The median time from diagnosis of cirrhosis to index hospitalization was 2 years (0.2–10). One thousand and seven hundred seven patients (33.2%) died within a year; 1,248 (24.3%) during index hospitalization. 59.5% (2,316/3,890) of the survivors, required at least one readmission, with additional mortality of 19.8% (459/2,316). ALC compared to non-ALC were more often (P<0.001) male (97.7% vs. 67.7%), younger (40–50 group, 36.2% vs. 20.2%; P<0.001) with higher liver related complications at baseline, (P<0.001 for each), sepsis: 20.3% vs. 14.9%; ascites: 82.2% vs. 65.9%; spontaneous bacterial peritonitis: 21.8% vs. 15.7%; hepatic encephalopathy: 41.0% vs. 25.0%; acute variceal bleeding: 32.0% vs. 23.7%; and acute kidney injury 30.5% vs. 19.6%. ALC patients had higher Child-Pugh (10.6±2.0 vs. 9.0±2.3), model for end-stage liver-disease scores (21.49±8.47 vs. 16.85±7.79), and higher mortality (42.3% vs. 27.3%, P<0.001) compared to non-ALC.

Conclusions
One-third of cirrhosis patients die in index hospitalization. 60% of the survivors require at least one rehospitalization within a year. ALC patients present with higher morbidity and mortality and at a younger age.

Citations

Citations to this article as recorded by  Crossref logo
  • Global, regional, and national burdens of alcohol-related cirrhosis among women from 1992 to 2021 and its predictions
    Zhou Zhang, Chun-mei Xu, Wei Chen, Kai-tao Yao, Ting Sun, Jing-hui Wang
    Scientific Reports.2025;[Epub]     CrossRef
  • Machine learning-based nomogram for mortality risk stratification in cirrhotic patients with sepsis: a single-center predictive model
    Xing-Cheng Zhang, Bo-Wen Li, Xi-Qun Lei, Nan-Bing Shan, Jun-Ping Wei, Zhong-Hua Lu, Yun Sun
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Insights into the Multifaceted Roles and Pleiotropic Functions of ALDH1L2 with Implications in Gastrointestinal Diseases and Cancer
    Partha Pratim Das, Subhash Medhi, Sangit Dutta, Anjan Jyoti Talukdar, Samudrala Gourinath
    Current Genetic Medicine Reports.2025;[Epub]     CrossRef
  • Burden of caregiving of alcohol related liver disease patients: a possible role of training and caregiver groups frequency. Proposal of a method, preliminary results
    Patrizia BALBINOT, Rinaldo PELLICANO, Gianni TESTINO
    Minerva Gastroenterology.2024;[Epub]     CrossRef
  • Etiological Spectrum of Cirrhosis in India: A Systematic Review and Meta-analysis
    Shekhar Swaroop, Manas Vaishnav, Umang Arora, Sagnik Biswas, Arnav Aggarwal, Soumya Sarkar, Puneet Khanna, Anshuman Elhence, Ramesh Kumar, Amit Goel, Shalimar
    Journal of Clinical and Experimental Hepatology.2024; 14(2): 101291.     CrossRef
  • Alcohol consumption, alcohol use disorder and organ transplantation
    Gianni TESTINO, Rinaldo PELLICANO, Fabio CAPUTO
    Minerva Gastroenterology.2024;[Epub]     CrossRef
  • Outcomes and Recurrence Rate of Esophageal Varices after Endoscopic Treatment in Patients with Alcoholic Cirrhosis and Viral Cirrhosis
    Yoshihiro Furuichi, Ryohei Nishiguchi, Takeshi Shimakawa, Tomoyuki Fujiwara, Koichiro Sato, Hiroyuki Kato
    Journal of Nippon Medical School.2024; 91(2): 180.     CrossRef
  • Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance
    Takao Miwa, Yuki Utakata, Tatsunori Hanai, Masashi Aiba, Shinji Unome, Kenji Imai, Koji Takai, Makoto Shiraki, Naoki Katsumura, Masahito Shimizu
    Journal of Gastroenterology.2024; 59(9): 849.     CrossRef
  • Incidence and risk factors of acute kidney injury in cirrhosis: a systematic review and meta-analysis of 5,202,232 outpatients, inpatients, and ICU-admitted patients
    Vasileios Lekakis, Aikaterini Gkoufa, John Vlachogiannakos, George V. Papatheodoridis, Evangelos Cholongitas
    Expert Review of Gastroenterology & Hepatology.2024; 18(7): 377.     CrossRef
  • Association of Alcohol Consumption With Liver Cancer and All-Cause Mortality in Chronic Hepatitis B Patients Without Cirrhosis
    BYUNGYOON Yun, JUYEON OH, SANG HOON AHN, JIN-HA Yoon, BEOM KYUNG Kim
    Clinical Gastroenterology and Hepatology.2023; 21(12): 3191.     CrossRef
  • Current and future treatment for alcoholic‐related liver diseases
    Eileen L. Yoon, Won Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1218.     CrossRef
  • Excess mortality in elderly hip fracture patients: An Indian experience
    Jaiben George, Vijay Sharma, Kamran Farooque, Vivek Trikha, Samarth Mittal, Rajesh Malhotra
    Chinese Journal of Traumatology.2023; 26(6): 363.     CrossRef
  • Overview of Complications in Cirrhosis
    Madhumita Premkumar, Anil C. Anand
    Journal of Clinical and Experimental Hepatology.2022; 12(4): 1150.     CrossRef
  • Liver cirrhosis
    Garima Singh, Suman Bala, Sonal Katoch, Lakhvinder Kaur, Anil Kumar, Abhishek Kumar, Alok Bharadwaj, Ardhariksa Zukhruf Kurniullah
    International journal of health sciences.2022; : 5547.     CrossRef
  • Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease
    Ji Ye Hyun, Seul Ki Kim, Sang Jun Yoon, Su Been Lee, Jin-Ju Jeong, Haripriya Gupta, Satya Priya Sharma, Ki Kwong Oh, Sung-Min Won, Goo Hyun Kwon, Min Gi Cha, Dong Joon Kim, Raja Ganesan, Ki Tae Suk
    International Journal of Molecular Sciences.2022; 23(15): 8749.     CrossRef
  • Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis
    Anca Trifan, Horia Minea, Adrian Rotaru, Carol Stanciu, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Ana-Maria Singeap, Irina Girleanu, Cristina Muzica, Laura Huiban, Tudor Cuciureanu, Stefan Chiriac, Catalin Sfarti, Camelia Cojocariu
    Medicina.2022; 58(12): 1859.     CrossRef
  • Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever
    Marta Tonon, Salvatore Piano
    Clinical and Molecular Hepatology.2021; 27(1): 94.     CrossRef
  • 8,957 View
  • 154 Download
  • 18 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Background/Aims
In recent years, greater assessment accuracy after transjugular intrahepatic portosystemic shunt (TIPS) to ascertain prognosis has become important in decompensated cirrhosis due to portal hypertension. The aim of this study was to assess the ratio of the portal pressure gradient (PPG) pre-TIPS (pre-PPG) to albumin (PPA), which influence ascites formation in cirrhotic patients in the 6-months after TIPS placement, and is a metric introduced in our study.
Methods
This was a retrospective cohort study of 58 patients with decompensated cirrhosis admitted to an academic hospital for the purpose of TIPS placement. We collected the following data: demographics, laboratory measures, and PPG during the TIPS procedure. Then we analyzed the association between the above data and ascites formation postTIPS in cirrhosis patients.
Results
Twenty-two patients with ascites and 28 without ascites were evaluated. Univariate and binary logistic regression analysis were adjusted for the following variables: to determine prognosis; Child-Pugh scores, lymphocyte count, platelet count, hemoglobin level, albumin level and pre-PPG or PPA. The outcome showed that PPA was better than pre-PPG and albumin for predicting ascites according to area under receiver operating characteristic curves and a statistical model that also showed PPA’s influence 6-months post-TIPS.
Conclusions
The combined measurement of pre-PPG and albumin, defined as PPA, may provide a better way to predict post-TIPS ascites in decompensated cirrhosis, which underlines the need for a large clinical trial in the future.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison of Endoscopic Ultrasound-guided Cyanoacrylate Injection and Transjugular Intrahepatic Portosystemic Shunt in the Prevention of Gastric Varices Rebleeding
    Zhuang Zeng, Zhihong Wang, Jing Jin, Fumin Zhang, Qianqian Zhang, Xuecan Mei, Derun Kong
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(5): 518.     CrossRef
  • Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis
    Yan Lan, Yue Yu, Xiuding Zhang, Xianbin Xu, Xia Yu, Huilan Tu, Shaoheng Ye, Haoda Weng, Yu Shi, Jifang Sheng
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Reduction of portosystemic gradient during transjugular intrahepatic portosystemic shunt achieves good outcome and reduces complications
    Shi-Hua Luo, Mi-Mi Zhou, Ming-Jin Cai, Shao-Lei Han, Xue-Qiang Zhang, Jian-Guo Chu
    World Journal of Gastroenterology.2023; 29(15): 2336.     CrossRef
  • Correlation between hepatic venous pressure gradient and portal pressure gradient in patients with autoimmune cirrhotic portal hypertension and collateral branches of the hepatic vein
    Bowen Liu, Dan Zhang, Chengbin Dong, Zhendong Yue, Lei Wang, Zhenhua Fan, Yifan Wu, Ke Zhang, Li Jiang, Huiguo Ding, Yuening Zhang, Jian Wang, Fuquan Liu
    Hepatology Research.2023; 53(11): 1084.     CrossRef
  • Comparison of transjugular intrahepatic portosystemic with endoscopic treatment plus anticoagulation for esophageal variceal bleeding and portal vein thrombosis in liver cirrhosis
    Wenyue Wu, Hejiao Zhang, Zhuang Zeng, Xi Wang, Derun Kong
    Scandinavian Journal of Gastroenterology.2022; 57(12): 1494.     CrossRef
  • The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?
    Beom Kyung Kim
    Clinical and Molecular Hepatology.2021; 27(1): 91.     CrossRef
  • Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
    Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
    Clinical and Molecular Hepatology.2021; 27(4): 535.     CrossRef
  • 8,878 View
  • 131 Download
  • 7 Web of Science
  • Crossref

Reviews

Liver fibrosis, cirrhosis, and portal hypertension

KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications
The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2018;24(3):230-277.
Published online July 9, 2018
DOI: https://doi.org/10.3350/cmh.2018.1005

Citations

Citations to this article as recorded by  Crossref logo
  • Esophagectomy in patients with liver cirrhosis: systematic review and meta-analysis of short-term outcomes
    Andrea Sozzi, Alberto Aiolfi, Gianluca Bonitta, Davide Bona, Luigi Bonavina, Antonio Biondi, Emanuele Rausa, Aleksandar Simić, Ognjan Skrobic, Calin Popa, Diana Schlanger
    Updates in Surgery.2025; 77(1): 143.     CrossRef
  • Evaluation of Human Albumin Use in Liver Transplantation Setting: A Tertiary Health Care Hospital Experience
    Hala Joharji, Mehwish Ateeq, Mohammad Al Amr, Dema Alissa, Ahmed Al-Jedai, Leenah Al Jawhari, Dalal AlKortas
    Saudi Journal of Clinical Pharmacy.2025; 4(2): 56.     CrossRef
  • Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
    Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(3): 1018.     CrossRef
  • The prediction of liver decompensation using hepatic collagen deposition assessed by computer-assisted image analysis with Masson’s trichrome stain
    Hae Won Yoo, Jae Woo Park, Min Jung Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Scandinavian Journal of Gastroenterology.2024; 59(1): 85.     CrossRef
  • New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32
    Tae Hyung Kim, Hyung Joon Yim, Young Kul Jung, Do Seon Song, Eileen L. Yoon, Hee Yeon Kim, Seong Hee Kang, Young Chang, Jeong-Ju Yoo, Baek Gyu Jun, Sung Won Lee, Jung Gil Park, Ji Won Park, Sung-Eun Kim, Tae Yeob Kim, Soung Won Jeong, Ki Tae Suk, Moon You
    Hepatology International.2024; 18(2): 500.     CrossRef
  • Differential diagnosis of ascites: etiologies, ascitic fluid analysis, diagnostic algorithm
    Li Du, Ning Wei, Rakhi Maiwall, Yuhu Song
    Clinical Chemistry and Laboratory Medicine (CCLM).2024; 62(7): 1266.     CrossRef
  • CIRSE Standards of Practice on Transjugular Intrahepatic Portosystemic Shunts
    Pierleone Lucatelli, Antonín Krajina, Romaric Loffroy, Roberto Miraglia, Claus Christian Pieper, Stéphanie Franchi-Abella, Bianca Rocco
    CardioVascular and Interventional Radiology.2024; 47(12): 1710.     CrossRef
  • New–onset ascites: a simplified diagnostic algorithm
    Monir Bahgat, Hany Mostafa, Osama Elhussieny
    Gastroenterology & Hepatology: Open access.2024; 15(6): 186.     CrossRef
  • Human Albumin Infusion for the Management of Liver Cirrhosis and Its Complications: An Overview of Major Findings from Meta-analyses
    Xiaojie Zheng, Zhaohui Bai, Ting Wang, Fernando G. Romeiro, Andrea Mancuso, Cyriac A. Philips, Yu J. Wong, Filipe G. Nery, Xingshun Qi
    Advances in Therapy.2023; 40(4): 1494.     CrossRef
  • Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma
    Chang Hun Lee, Hye Jin Kang, Song Yi Yu, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Clinical Characteristics and Early Diagnosis of Spontaneous Fungal Peritonitis/Fungiascites in Hospitalized Cirrhotic Patients with Ascites: A Case–Control Study
    Yingying Jiang, Chunlei Fan, Yan Dang, Wenmin Zhao, Lingna Lv, Jinli Lou, Lei Li, Huiguo Ding
    Journal of Clinical Medicine.2023; 12(9): 3100.     CrossRef
  • The Role of Correcting Structural and Functional Albumin Properties in Ascites Control in Decompensated Cirrhotic Patients
    A. A. Turkina, M. V. Maevskaya, M. S. Zharkova, V. T. Ivashkin
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2023; 33(3): 43.     CrossRef
  • Evidence-based hyponatremia management in liver disease
    Ji Young Ryu, Seon Ha Baek, Sejoong Kim
    Clinical and Molecular Hepatology.2023; 29(4): 924.     CrossRef
  • Pulmonary Complications in Patients with Liver Cirrhosis
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    The Korean Journal of Gastroenterology.2023; 82(5): 213.     CrossRef
  • Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis
    Dibya L. Praharaj, Anil C. Anand
    Journal of Clinical and Experimental Hepatology.2022; 12(2): 575.     CrossRef
  • Refractory ascites of complex genesis in patients with a severe combined form of extrahepatic portal hypertension
    G. V. Manukyan, R. A. Musin, V. M. Lebezev, S. B. Zhigalova, E. A. Kitsenko, D. V. Burenchev, V. A. Cherkasov, S. A. Rizaeva
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2022; 27(1): 87.     CrossRef
  • CLINICAL AND LABORATORY MANIFESTATIONS OF ALCOHOLIC LIVER DISEASE AT THE CIRRHOSIS STAGE ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE DEPENDING ON DISEASE COMPENSATION
    N. R. Matkovska, N. H. Virstiuk, U. V. Balan, I. O. Kostitska, M. S. Voloshynovych, N. V. Chaplynska, V. T. Rudnyk
    World of Medicine and Biology.2022; 18(79): 94.     CrossRef
  • Renal Dysfunction in Patients with Liver Cirrhosis
    Mahmoud Sobh, Mohamed Abdalbary, Mostafa Abdelsalam, Amr El-Husseini Mohamed
    Digestive Disease Interventions.2022; 06(02): 131.     CrossRef
  • Korean Society of Nephrology 2022 Recommendations on controversial issues in diagnosis and management of hyponatremia
    Yeonhee Lee, Kyung Don Yoo, Seon Ha Baek, Yang Gyun Kim, Hyo Jin Kim, Ji Young Ryu, Jin Hyuk Paek, Sang Heon Suh, Se Won Oh, Jeonghwan Lee, Jong Hyun Jhee, Jin-Soon Suh, Eun Mi Yang, Young Ho Park, Yae Lim Kim, Miyoung Choi, Kook-Hwan Oh, Sejoong Kim
    Kidney Research and Clinical Practice.2022; 41(Suppl 1): S1.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Psoas muscle index predicts time to rehospitalization in liver cirrhosis: An observational study
    Florian Hentschel, Theresa Schwarz, Stefan Lüth, Andreas G. Schreyer
    Medicine.2022; 101(36): e30259.     CrossRef
  • Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
    Xiaoyuan Gou, Wenyuan Jia, Chuangye He, Xulong Yuan, Jing Niu, Jiao Xu, Na Han, Ying Zhu, Wenlan Wang, Jun Tie
    European Radiology.2022; 33(5): 3407.     CrossRef
  • Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events
    Joo Hyun Oh, Myung Ji Goh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
    Digestive Diseases and Sciences.2021; 66(8): 2816.     CrossRef
  • Impact of acute kidney injury on survival in patients with chronic hepatitis C: a retrospective cohort study
    Hankyu Jeon, Jae Heon Kim, Sang Soo Lee, Hee Jin Kim, Ra Ri Cha, Hyun Chin Cho, Jae Min Lee, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok-Jae Lee
    BMC Infectious Diseases.2021;[Epub]     CrossRef
  • Bedside risk‐scoring model for predicting 6‐week mortality in cirrhotic patients undergoing endoscopic band ligation for acute variceal bleeding
    Jung Hee Kim, Se Woo Park, Jang Han Jung, Da Hae Park, Chang Seok Bang, Chan Hyuk Park, Ji Won Park, Jae Gun Park
    Journal of Gastroenterology and Hepatology.2021; 36(7): 1935.     CrossRef
  • Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis
    Han Ah Lee, Joon Young Jung, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyonggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Yeon Seok Seo
    Gut and Liver.2021; 15(4): 599.     CrossRef
  • Inguinal Hernias in Cirrhotic Patients: From Diagnosis to Treatment
    Stylianos Kykalos, Nikolaos Machairas, Evangelia Ntikoudi, Panagiotis Dorovinis, Ernesto P Molmenti, Georgios C Sotiropoulos
    Surgical Innovation.2021; 28(5): 620.     CrossRef
  • A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects
    Cuiyun Li, Wei Xiang, Min Wu, Hong Zhang, Jianqiu Cheng, Tao Yang, Jiajia Mai, Xiumei Chi, Xiuzhu Gao, Yanhua Ding, Junqi Niu
    European Journal of Pharmaceutical Sciences.2021; 165: 105923.     CrossRef
  • Recurrent ascites in a man with liver cirrhosis: A case report
    Rui Qi Xia, Wei Yuan, Mao Song Ye, Jian Wang, Xiao Qing Zeng, Shi Yao Chen
    Journal of Digestive Diseases.2021; 22(12): 727.     CrossRef
  • Clinical impact of the treatment modality on small, solitary, recurrent intrahepatic hepatocellular carcinomas after primary liver resection
    Hyo-Sin Kim, Nam-Joon Yi, Jong Man Kim, Jae-Won Joh, Kwang-Woong Lee, Kyung-Suk Suh
    Annals of Surgical Treatment and Research.2021; 101(2): 85.     CrossRef
  • Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy
    Seogsong Jeong, Yuri Cho, Sang Min Park, Won Kim
    Journal of Clinical Gastroenterology.2021; 55(9): e77.     CrossRef
  • Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol
    Jae Hyun Yoon, Chung Hwan Jun, Jeong Han Kim, Eileen L. Yoon, Byung Seok Kim, Jeong Eun Song, Ki Tae Suk, Moon Young Kim, Seong Hee Kang
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • A Systematic Review of Herbal Medicine in the Treatment of Cirrhotic Ascites
    Seungmo Kim, Yuri Lee, Nakyung Cho, Hongsik Choi, Kyungsoon Kim
    Journal of Korean Medicine.2021; 42(4): 222.     CrossRef
  • A Systematic Review of Medical Nutrition Therapy Guidelines for Liver Cirrhosis: Do We Agree?
    Xenophon Theodoridis, Maria G. Grammatikopoulou, Arianna Petalidou, Stamatia‐Maria Kontonika, Spyros P. Potamianos, Dimitrios P. Bogdanos
    Nutrition in Clinical Practice.2020; 35(1): 98.     CrossRef
  • Prognosis of surgical hernia repair in cirrhotic patients with refractory ascites
    S. W. Kim, M. A. Kim, Y. Chang, H. Y. Lee, J. S. Yoon, Y. B. Lee, E. J. Cho, J.-H. Lee, S. J. Yu, J.-H. Yoon, K. J. Park, Y. J. Kim
    Hernia.2020; 24(3): 481.     CrossRef
  • Effect of acute kidney injury on long‐term outcomes of spontaneous bacterial peritonitis in cirrhotic patients using the International Club of Ascites‐acute kidney injury criteria
    Won Sohn, Jung Hee Kim, Ju‐Yeon Cho
    Journal of Gastroenterology and Hepatology.2020; 35(5): 870.     CrossRef
  • Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study
    Jung Gil Park, Won Young Tak, Soo Young Park, Young Oh Kweon, Woo Jin Chung, Byoung Kuk Jang, Si Hyun Bae, Heon Ju Lee, Jae Young Jang, Ki Tae Suk, Myung Jin Oh, Jeong Heo, Hyun Young Woo, Se Young Jang, Yu Rim Lee, June Sung Lee, Do Young Kim, Seok Hyun
    Nutrients.2020; 12(5): 1429.     CrossRef
  • Risk of Liver Cirrhosis and Hepatocellular Carcinoma after Fontan Operation: A Need for Surveillance
    Jun Sik Yoon, Dong Ho Lee, Eun Ju Cho, Mi Kyoung Song, Young Hun Choi, Gi Beom Kim, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Haeryoung Kim, Yoon Jun Kim, Jung-Hwan Yoon, Eun Jung Bae
    Cancers.2020; 12(7): 1805.     CrossRef
  • Propofol alone prevents worsening hepatic encephalopathy rather than midazolam alone or combined sedation after esophagogastroduodenoscopy in compensated or decompensated cirrhotic patients
    Joonho Jeong, Kyoungwon Jung, Kwang Il Seo, Byung Cheol Yun, Byung Hoon Han, Sang Uk Lee, Won Moon
    European Journal of Gastroenterology & Hepatology.2020; 32(8): 1054.     CrossRef
  • Ascites management by cell-free concentrated ascites reinfusion therapy during recovery from drug-induced acute liver injury: a case report
    Koya Yasuda, Mea Asou, Tomohiko Asakawa, Makoto Araki
    Journal of Medical Case Reports.2020;[Epub]     CrossRef
  • Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk
    Cancers.2020; 12(11): 3347.     CrossRef
  • Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study
    Tae Hyung Kim, Yeon Seok Seo, Seong Hee Kang, Moon Young Kim, Sang Gyune Kim, Hyo Young Lee, Jeong‐Hoon Lee, Young‐Sun Lee, Ji Hoon Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Young Kul Jung, Hyonggin An, Hyung Joon Yim, Young Seok Kim, Soon Ho Um
    Liver International.2020; 40(12): 3083.     CrossRef
  • Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence
    Jingqiao Zhang, Martin Rössle, Xinmiao Zhou, Jiao Deng, Lu Liu, Xingshun Qi
    Current Medical Research and Opinion.2019; 35(5): 859.     CrossRef
  • Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex
    Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Bora Lee, Min Hee Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Young Don Kim, Gab Jin Cheon
    Journal of Hepatology.2019; 70(5): 847.     CrossRef
  • The therapeutic potential of induced hepatocyte-like cells generated by direct reprogramming on hepatic fibrosis
    Suhyun Park, Seon In Hwang, Jonghun Kim, Seoyeon Hwang, Sohee Kang, Sera Yang, Jonghwa Kim, Wonseok Kang, Kyun-Hwan Kim, Dong Wook Han, Yong-Han Paik
    Stem Cell Research & Therapy.2019;[Epub]     CrossRef
  • Shear-Wave Dispersion Slope from US Shear-Wave Elastography: Detection of Allograft Damage after Liver Transplantation
    Dong Ho Lee, Jae Young Lee, Jae Seok Bae, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Haeryoung Kim, Kyung Bun Lee, Joon Koo Han
    Radiology.2019; 293(2): 327.     CrossRef
  • Various Treatment Modalities in Hepatic Hydrothorax: What Is Safe and Effective?
    Jae Hyun Yoon, Hee Joon Kim, Chung Hwan Jun, Sung Bum Cho, Yochun Jung, Sung Kyu Choi
    Yonsei Medical Journal.2019; 60(10): 944.     CrossRef
  • A Novel Biomarker for the Acute Kidney Injury in the Cirrhotic Patients
    Nae-Yun Heo
    The Korean Journal of Gastroenterology.2019; 74(4): 191.     CrossRef
  • 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines for Ascites and Related Complications: What Has Been Changed from the 2011 KASL Clinical Practice Guidelines?
    Yeon Seok Seo
    The Korean Journal of Gastroenterology.2018; 72(4): 179.     CrossRef
  • Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
    Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • 39,893 View
  • 826 Download
  • 46 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Acute kidney injury in liver cirrhosis: new definition and application
Florence Wong
Clin Mol Hepatol 2016;22(4):415-422.
Published online December 14, 2016
DOI: https://doi.org/10.3350/cmh.2016.0056
The traditional diagnostic criteria of renal dysfunction in cirrhosis are a 50% increase in serum creatinine (SCr) with a final value above 1.5 mg/dL. This means that patients with milder degrees of renal dysfunction are not being diagnosed, and therefore not offered timely treatment. The International Ascites Club in 2015 adapted the term acute kidney injury (AKI) to represent acute renal dysfunction in cirrhosis, and defined it by an increase in SCr of 0.3 mg/dL (26.4 µmoL/L) in <48 hours, or a 50% increase in SCr from a baseline within ≤3 months. The severity of AKI is described by stages, with stage 1 represented by these minimal changes, while stages 2 and 3 AKI by 2-fold and 3-fold increases in SCr respectively. Hepatorenal syndrome (HRS), renamed AKI-HRS, is defined by stage 2 or 3 AKI that fulfils all other diagnostic criteria of HRS. Various studies in the past few years have indicated that these new diagnostic criteria are valid in the prediction of prognosis for patients with cirrhosis and AKI. The future in AKI diagnosis may include further refinements such as inclusion of biomarkers that can identify susceptibility for AKI, differentiating the various prototypes of AKI, or track its progression.

Citations

Citations to this article as recorded by  Crossref logo
  • The role of urinary biomarkers in the diagnosis of acute kidney injury in patients with liver cirrhosis
    Willian Sacco Altran, Luiz Felipe de Sousa, Renan dos Santos Cortinhas, Daniela Ponce
    Scientific Reports.2025;[Epub]     CrossRef
  • Machine learning-based prediction model for 28-day mortality in acute kidney injury patients with liver cirrhosis: A MIMIC-IV database analysis
    Luyu Chai, Yuxiang Zhou, Nan Zhou, Yao Xiao, Renqi Pang, Sona Frankova
    PLOS One.2025; 20(9): e0328662.     CrossRef
  • Severity of Acute Portal Hypertension Determines the Clinical Outcomes in Severe Alcoholic Hepatitis
    Ankur Jindal, Manoj K. Sharma, Rajan Vijayaraghavan, Shasthry SM, Guresh Kumar, Shiv K. Sarin
    Digestive Diseases and Sciences.2024; 69(1): 298.     CrossRef
  • Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
    Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, Yeon Seok Seo, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun
    Gut and Liver.2024; 18(2): 305.     CrossRef
  • Early Versus Standard Initiation of Terlipressin for Acute Kidney Injury in ACLF: A Randomized Controlled Trial (eTerli Study)
    Ankur Jindal, Hitesh Singh, Guresh Kumar, Vinod Arora, Manoj Kumar Sharma, Rakhi Maiwall, V. Rajan, Harsh Vardhan Tewathia, Chitranshu Vasishtha, Shiv Kumar Sarin
    Digestive Diseases and Sciences.2024; 69(6): 2204.     CrossRef
  • Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial
    Abhijeet Ranjan, Ankur Jindal, Rakhi Maiwall, Chitranshu Vashishtha, Rajan Vijayaraghavan, Vinod Arora, Shiv K. Sarin
    Hepatology International.2024; 18(4): 1261.     CrossRef
  • Acute Kidney Injury in Chronic Liver Disease in Northwest India: Still a Battle to Conquer
    Disha Saxena, Manoj Yadav, Tarun Kumar, Sanjeev Sharma, Pankaj Beniwal, Vinay Malhotra, Dhananjai Agarwal, Sandeep Nijhawan
    Indian Journal of Nephrology.2024; 34: 317.     CrossRef
  • Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis
    Xiaoyan Wang, Wei Xu, Lin Yao, Yu Jie, Zhenjun Gao, Yu Fan
    Current Medicinal Chemistry.2024; 31(25): 3977.     CrossRef
  • An early warning model for predicting major adverse kidney events within 30 days in acute pancreatitis patients
    Qiulong Wang, Juantao Lv, Dongdong Chen, Xiaojun Yang
    Renal Failure.2024;[Epub]     CrossRef
  • The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury
    Ahmed M. Abd El Wahab, Abeer Awadeen, Mostafa M. Mansour, Rasha Shemies
    Therapeutic Apheresis and Dialysis.2023; 27(3): 419.     CrossRef
  • Integrated bioinformatical and in vitro study on drug targets for liver cirrhosis based on unsupervised consensus clustering and immune cell infiltration
    Qingjia Chi, Di Wang, Ting Sun, Hua-Ping Liang
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Hepatorenaal syndroom na embolisatie van een splenorenale shunt
    R. Devloo, J. Decaestecker, B. Maes
    Tijdschrift voor Geneeskunde.2023;[Epub]     CrossRef
  • Urine neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury and prognosis in decompensated chronic liver disease: A prospective study
    Rohan Vijay Yewale, Balakrishnan Siddartha Ramakrishna, Giriprasad Venugopal, Babu Vinish Doraiswami, Kayalvizhi Rajini
    Indian Journal of Gastroenterology.2023; 42(1): 106.     CrossRef
  • Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
    Mattias Mandorfer, Elmar Aigner, Manfred Cejna, Arnulf Ferlitsch, Christian Datz, Tilmann Gräter, Ivo Graziadei, Michael Gschwantler, Stephanie Hametner-Schreil, Harald Hofer, Mathias Jachs, Alexander Loizides, Andreas Maieron, Markus Peck-Radosavljevic,
    Wiener klinische Wochenschrift.2023; 135(S3): 493.     CrossRef
  • Acute Kidney Injury in Liver Cirrhosis
    Rose Mary Attieh, Hani M. Wadei
    Diagnostics.2023; 13(14): 2361.     CrossRef
  • Renal dysfunctions and liver disease: a brief update on management with particular attention to hepatorenal syndrome
    Monica SURACE, Immacolata ANDRIA, Giovanni VALENTINI
    Minerva Gastroenterology.2023;[Epub]     CrossRef
  • Hepatorenal syndrome: Current concepts and future perspectives
    Chan-Young Jung, Jai Won Chang
    Clinical and Molecular Hepatology.2023; 29(4): 891.     CrossRef
  • Addition of Kidney Dysfunction Type to MELD-Na for the Prediction of Survival in Cirrhotic Patients Awaiting Liver Transplantation in Comparison with MELD 3.0 with Albumin
    Kyeong-Min Yeom, Jong-In Chang, Jeong-Ju Yoo, Ji Eun Moon, Dong Hyun Sinn, Young Seok Kim, Sang Gyune Kim
    Diagnostics.2023; 14(1): 39.     CrossRef
  • Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg
    Ankur Jindal, Shiv K. Sarin, Manoj Kumar, Guresh Kumar
    Digestive Diseases and Sciences.2022; 67(11): 5280.     CrossRef
  • Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment
    Zhixiang Mou, Tianjun Guan, Lan Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Acute Liver Failure in Children
    Divya G. Sabapathy, Moreshwar S. Desai
    Pediatric Clinics of North America.2022; 69(3): 465.     CrossRef
  • Acute nierschade bij patiënten met cirrose: differentiaaldiagnose en praktische aanpak
    A.-M. Van der Biest, J.M.K. De Filette, E. Hoste, P. Peeters
    Tijdschrift voor Geneeskunde.2022;[Epub]     CrossRef
  • [Retracted] Automatic Detection and Classification of Epileptic Seizures in Patients with Liver Cirrhosis and Overlapping Hev Infection Based on Deep Multimodal Fusion Technology
    Jianan Yu, Rui Min, Yun Yu, Xiaorui Hu, Xiandong Fu, Nannan Chi, Sandip K Mishra
    Contrast Media & Molecular Imaging.2022;[Epub]     CrossRef
  • Management of AKI in Patients with Cirrhosis
    Kevin R. Regner, Swetha Rani Kanduri, Juan Carlos Q. Velez
    Current Treatment Options in Gastroenterology.2022; 20(3): 295.     CrossRef
  • Hepatorenal syndrome: new insights about treatment (part III)
    E. S. Krutikov, A. N. Vostrikova, S. N. Krutikov
    South Russian Journal of Therapeutic Practice.2022; 3(4): 32.     CrossRef
  • Applicability of the Chronic Liver Failure-Consortium score in patients with cirrhosis and bacterial infections: a single-clinic experience
    D.I. Haurylenka, N.N. Silivontchik
    GASTROENTEROLOGY.2022; 55(4): 239.     CrossRef
  • An Integrated Review of the Hepatorenal Syndrome
    Alicia S. Ojeda-Yuren, Eira Cerda-Reyes, Maria R. Herrero-Maceda, Graciela Castro-Narro, Salvatore Piano
    Annals of Hepatology.2021; 22: 100236.     CrossRef
  • Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis
    Lukas Otero Sanchez, Claire Francoz
    United European Gastroenterology Journal.2021; 9(2): 220.     CrossRef
  • The Role of Urinary N-Acetyl-β-d-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study
    Jeong-Ju Yoo, Jung Hyun Kwon, Young Seok Kim, Soon Woo Nam, Ji Won Park, Hee Yeon Kim, Chang Wook Kim, Seung Kak Shin, Young Eun Chon, Eun Sun Jang, Sook-Hyang Jeong, Jin Woo Lee, Do Seon Song, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Young Kul Jung, Hyung
    Journal of Clinical Medicine.2021; 10(19): 4328.     CrossRef
  • The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA
    Michael Makar, Debashis Reja, Abhishek Chouthai, Savan Kabaria, Anish Vinit Patel
    European Journal of Gastroenterology & Hepatology.2021; 33(6): 905.     CrossRef
  • Clinical outcomes and prognostic factors of mortality in liver cirrhosis patients on continuous renal replacement therapy in two tertiary hospitals in Korea
    You Hyun Jeon, Il Young Kim, Gum Sook Jang, Sang Heon Song, Eun Young Seong, Dong Won Lee, Soo Bong Lee, Hyo Jin Kim
    Kidney Research and Clinical Practice.2021; 40(4): 687.     CrossRef
  • Kidney Failure after Liver Transplantation
    Eloïse Colliou, Arnaud Del Bello, David Milongo, Fabrice Muscari, Marion Vallet, Ivan Tack, Nassim Kamar
    Transplantology.2021; 2(3): 315.     CrossRef
  • Acute kidney injury and hepatorenal syndrome in cirrhosis
    Kapil Gupta, Abhishek Bhurwal, Cindy Law, Scott Ventre, Carlos D Minacapelli, Savan Kabaria, You Li, Christopher Tait, Carolyn Catalano, Vinod K Rustgi
    World Journal of Gastroenterology.2021; 27(26): 3984.     CrossRef
  • Renal Dysfunction in Chronic Liver Disease
    Rohan Yewale, Balakrishnan S. Ramakrishna
    Gastroenterology, Hepatology and Endoscopy Practice.2021; 1(1): 2.     CrossRef
  • Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure
    Vinod Arora, Rakhi Maiwall, Vijayaraghavan Rajan, Ankur Jindal, Saggere Muralikrishna Shasthry, Guresh Kumar, Priyanka Jain, Shiv Kumar Sarin
    Hepatology.2020; 71(2): 600.     CrossRef
  • Role of Endotoxemia in Causing Renal Dysfunction in Cirrhosis
    Jennifer L Peng, Witina Techasatian, Takashi Hato, Suthat Liangpunsakul
    Journal of Investigative Medicine.2020; 68(1): 26.     CrossRef
  • Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores
    Tae Hyung Kim, Seung Gyu Yun, Jimi Choi, Hyun Gil Goh, Han Ah Lee, Sun Young Yim, Seong Ji Choi, Young-Sun Lee, Eileen L. Yoon, Young Kul Jung, Yeon Seok Seo, Ji Hoon Kim, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Renal Dysfunction After Liver Transplantation: Effect of Donor Type
    Dagmar Kollmann, Shuet Fong Neong, Roizar Rosales, Bettina E. Hansen, Gonzalo Sapisochin, Stuart McCluskey, Mamatha Bhat, Mark S. Cattral, Les Lilly, Ian D. McGilvray, Anand Ghanekar, David R. Grant, Markus Selzner, Florence S. H. Wong, Nazia Selzner
    Liver Transplantation.2020; 26(6): 799.     CrossRef
  • Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg
    Ankur Jindal, Ankit Bhardwaj, Guresh Kumar, Shiv Kumar Sarin
    American Journal of Gastroenterology.2020; 115(10): 1624.     CrossRef
  • Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study
    Tae Hyung Kim, Yeon Seok Seo, Seong Hee Kang, Moon Young Kim, Sang Gyune Kim, Hyo Young Lee, Jeong‐Hoon Lee, Young‐Sun Lee, Ji Hoon Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Young Kul Jung, Hyonggin An, Hyung Joon Yim, Young Seok Kim, Soon Ho Um
    Liver International.2020; 40(12): 3083.     CrossRef
  • Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Won Sohn, Cheol Bae Ham, Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon, Byung Ik Kim, Do Young Kim
    PLOS ONE.2020; 15(12): e0243780.     CrossRef
  • Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N‐acetyl‐β‐D‐glucosaminidase
    Tae Hyung Kim, Han Ah Lee, Yeon Seok Seo, Yoo Ra Lee, Sun Young Yim, Young Sun Lee, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
    Journal of Gastroenterology and Hepatology.2019; 34(1): 234.     CrossRef
  • Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex
    Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Bora Lee, Min Hee Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Young Don Kim, Gab Jin Cheon
    Journal of Hepatology.2019; 70(5): 847.     CrossRef
  • Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
    Jennifer Lehmann, Michael Praktiknjo, Mette Juul Nielsen, Robert Schierwagen, Carsten Meyer, Daniel Thomas, Francesco Violi, Christian P. Strassburg, Flemming Bendtsen, Søren Møller, Aleksander Krag, Morten Asser Karsdal, Diana Julie Leeming, Jonel Trebic
    Liver International.2019; 39(5): 885.     CrossRef
  • Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult‐to‐manage hydrothorax in cirrhosis
    Ankur Jindal, Amar Mukund, Guresh Kumar, Shiv K. Sarin
    Liver International.2019; 39(11): 2164.     CrossRef
  • Emerging Gram‑positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study
    Jingjing Guo, Jingren Shi, Huizhu Wang, Hui Chen, Shunai Liu, Junnan Li, Yajie Wang
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • RETROSPECTIVE ANALYSIS OF PNEUMONIA IN CIRRHOTIC PATIENTS
    D. Haurylenka, N. Silivontchik, O. Zhyhaltsova-Kuchinskaya
    Hepatology and Gastroenterology.2019; 3(1): 43.     CrossRef
  • Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon
    Seong Hee Kang, Moon Young Kim, Soon Koo Baik
    Hepatology International.2018; 12(S1): 112.     CrossRef
  • Cholemic nephropathy – Historical notes and novel perspectives
    Elisabeth Krones, Marion J. Pollheimer, Alexander R. Rosenkranz, Peter Fickert
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2018; 1864(4): 1356.     CrossRef
  • Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study
    Ki Tae Suk, Moon Young Kim, Soung Won Jeong, Jae Young Jang, Yoon Ok Jang, Soon Koo Baik
    Digestive Diseases and Sciences.2018; 63(1): 248.     CrossRef
  • Serum cystatin C level: An excellent predictor of mortality in patients with cirrhotic ascites
    Yeon Seok Seo, Soo Young Park, Moon Young Kim, Sang Gyune Kim, Jun Yong Park, Hyung Joon Yim, Byoung Kuk Jang, Seung Ha Park, Ji Hoon Kim, Ki Tae Suk, Jin Dong Kim, Tae Yeob Kim, Eun Young Cho, Jun Sung Lee, Soung Won Jung, Jae Young Jang, Hyonggin An, Wo
    Journal of Gastroenterology and Hepatology.2018; 33(4): 910.     CrossRef
  • Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    Baek Gyu Jun, Woong Cheul Lee, Jae Young Jang, Soung Won Jeong, Young Don Kim, Gab Jin Cheon, Yun Nah Lee, Sang Gyune Kim, Young Seok Kim, Young Sin Cho, Sae Hwan Lee, Hong Soo Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Hepatic damage exacerbates cisplatin-induced acute kidney injury in Sprague-Dawley rats
    Ji Su Kim, Ji Yeon Son, Kyeong Seok Kim, Hyun Jung Lim, Mee-Young Ahn, Seung Jun Kwack, Young-Mi Kim, Kwang Youl Lee, Jaewon Lee, Byung Mu Lee, Hyung Sik Kim
    Journal of Toxicology and Environmental Health, Part A.2018; 81(11): 397.     CrossRef
  • Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis
    Lei Lei, Liang Ping Li, Zhen Zeng, Jing Xi Mu, Xue Yang, Chao Zhou, Zhi Lan Wang, Hu Zhang
    Scientific Reports.2018;[Epub]     CrossRef
  • “Normal” Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis
    Giuseppe Cullaro, Meyeon Park, Jennifer C. Lai
    Hepatology.2018; 68(5): 1953.     CrossRef
  • Serum sodium, model for end-stage liver disease, and a recent invasive procedure are risk factors for severe acute-on-chronic liver failure and death in cirrhotic patients hospitalized with bacterial infection
    Tirzah M. Lopes-Secundo, Tiago Sevá-Pereira, Bárbara R. Correa, Natalie C.M. Silva, Marcello R. Imbrizi, Marlone Cunha-Silva, Elza C. Soares, Jazon R.S. Almeida
    European Journal of Gastroenterology & Hepatology.2018; 30(9): 1055.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Acute kidney injury network criteria as a prognostic factor in cirrhotic patients with spontaneous bacterial peritonitis
    Salah El-Gamal, Hazem Hakim El-Beltagy El-Menshawy, Neveen F. Abbas, Omar El-Metwally
    The Egyptian Journal of Internal Medicine.2018; 30(4): 264.     CrossRef
  • Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis
    Gaeun Kim, Ji Hye Huh, Kyong Joo Lee, Moon Young Kim, Kwang Yong Shim, Soon Koo Baik
    Digestive Diseases and Sciences.2017; 62(4): 1067.     CrossRef
  • Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome
    Theresa Bucsics, Elisabeth Krones
    Gastroenterology Report.2017; 5(2): 127.     CrossRef
  • Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
    Thomas Reiberger, Andreas Püspök, Maria Schoder, Franziska Baumann-Durchschein, Theresa Bucsics, Christian Datz, Werner Dolak, Arnulf Ferlitsch, Armin Finkenstedt, Ivo Graziadei, Stephanie Hametner, Franz Karnel, Elisabeth Krones, Andreas Maieron, Mattias
    Wiener klinische Wochenschrift.2017; 129(S3): 135.     CrossRef
  • Managing Issues in Dialysis for the Patient with AKI
    Eric Judd, Ashita Tolwani
    Clinical Journal of the American Society of Nephrology.2017; 12(9): 1538.     CrossRef
  • 18,699 View
  • 770 Download
  • 61 Web of Science
  • Crossref

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction
Maha Mohammad Elsabaawy, Shimaa Rashad Abdelhamid, Ayman Alsebaey, Eman Abdelsamee, Manar Abdelaal Obada, Tary Abdelhamid Salman, Eman Rewisha
Clin Mol Hepatol 2015;21(4):365-371.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.365
Background/Aims

Ascites is a dreadful complication of liver cirrhosis associated with short survival. Large volume paracentesis (LVP) is used to treat tense or refractory ascites. Paracentesis induced circulatory dysfunction (PICD) develops if no plasma expanders are given with ominous complications. To study the effect of ascites flow rate on PICD development.

Methods

Sixty patients with cirrhosis and tense ascites underwent LVP of 8 L were randomized into 3 equal groups of different flow rate extraction; group I (80 mL/minute), group II (180 mL/minute) and group III (270 mL/minute). Plasma renin activity (PRA) was measured baseline and on day six. PICD was defined as increase in PRA >50% of the pretreatment value.

Results

In group I through 3; the mean age was (52.5±9.4 vs. 56.4±8.5 vs. 55.8±7.1 years; P>0.05), mean arterial pressure (81.4±5.6 vs. 81.5±7 vs. 79.5±7.2 mmHg; P>0.05), MELD (17.6±4.1 vs. 15.8±4.1 vs. 14.7±4.5). Baseline PRA was comparable (1,366.0±1244.9 vs. 1,151.3±1,444.8 vs. 951.9±1,088 pg/mL; P>0.05). There was no statistically significant (P>0.05) flow mediated changes (Δ) of creatinine (0.23±0.27 vs. 0.38±0.33 vs. 0.26±0.18 mg/dL), MELD (1.25±5.72 vs. 1.70±2.18 vs. 1.45±2.21) or PRA (450.93±614.10 vs. 394.61±954.64 vs. 629.51±1,116.46 pg/mL). PICD was detected in a similar frequency in the three groups (P>0.05). On univariate logistic analysis only female sex was a fairly significant PICD predictor (Wald 3.85, odds ratio 3.14; P=0.05).

Conclusions

The ascites flow rate does not correlate with PICD development.

Citations

Citations to this article as recorded by  Crossref logo
  • Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial
    Hyung Joon Yim, Tae Hyung Kim, Sang Jun Suh, Sun Young Yim, Young Kul Jung, Yeon Seok Seo, Seong Hee Kang, Moon Young Kim, Soon Koo Baik, Hong Soo Kim, Young Seok Kim, Soo Young Park, Byung Ik Kim, Jun Yong Park, Jeong Heo, Joo Hyun Sohn, Nae-Yun Heo, Kwa
    American Journal of Gastroenterology.2023; 118(4): 654.     CrossRef
  • Use of laparocentesis in the treatment of ascites in patients with liver cirrhosis
    E. V. Mahiliavets, Y. N. Bozhko, O. N. Mahiliavets
    Proceedings of the National Academy of Sciences of Belarus, Medical series.2021; 18(3): 362.     CrossRef
  • Concordance of 24- and 48-h diagnostic follow-up ascitic fluid polymorphonuclear leukocyte count in the guidance of the antibiotic therapy in spontaneous bacterial peritonitis
    Hanaa Mostafa Badran, Maha Mohammad Elsabaawy, Mohamed Azazy Mahmoud, Heba Samy Ghanem, Ayman Alsebaey, Warda Othman
    Egyptian Liver Journal.2021;[Epub]     CrossRef
  • Clinical Progress Note: Intravenous Human Albumin in Patients With Cirrhosis
    Suchita Shah Sata, Omobonike Oloruntoba Sanders, Catherine A Curley
    Journal of Hospital Medicine.2021; 16(12): 738.     CrossRef
  • Pathophysiology and Prevention of Paracentesis-induced Circulatory Dysfunction: A Concise Review
    Anand V Kulkarni, Pramod Kumar, Mithun Sharma, T R Sowmya, Rupjyoti Talukdar, Padaki Nagaraj Rao, D Nageshwar Reddy
    Journal of Clinical and Translational Hepatology.2020; 8(X): 1.     CrossRef
  • High efficacy of low-dose albumin infusion in the prevention of paracentesis-induced circulatory dysfunction
    Ayman Alsebaey, Eman Rewisha, Imam Waked
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Paracentesis-induced circulatory dysfunction: are there albumin alternatives?
    Ayman Alsebaey, Eman Rewisha, Imam Waked
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study
    Tae Hyung Kim, Yeon Seok Seo, Seong Hee Kang, Moon Young Kim, Sang Gyune Kim, Hyo Young Lee, Jeong‐Hoon Lee, Young‐Sun Lee, Ji Hoon Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Young Kul Jung, Hyonggin An, Hyung Joon Yim, Young Seok Kim, Soon Ho Um
    Liver International.2020; 40(12): 3083.     CrossRef
  • Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N‐acetyl‐β‐D‐glucosaminidase
    Tae Hyung Kim, Han Ah Lee, Yeon Seok Seo, Yoo Ra Lee, Sun Young Yim, Young Sun Lee, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
    Journal of Gastroenterology and Hepatology.2019; 34(1): 234.     CrossRef
  • Current approaches to the management of patients with cirrhotic ascites
    Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev
    World Journal of Gastroenterology.2019; 25(28): 3738.     CrossRef
  • Prevention of the Osmotic Demyelination Syndrome After Liver Transplantation: A Multidisciplinary Perspective
    J.F. Crismale, K.A. Meliambro, S. DeMaria, D.B. Bronster, S. Florman, T.D. Schiano
    American Journal of Transplantation.2017; 17(10): 2537.     CrossRef
  • What we know about paracentesis induced circulatory dysfunction?
    Jeong Han Kim
    Clinical and Molecular Hepatology.2015; 21(4): 349.     CrossRef
  • 13,785 View
  • 124 Download
  • 12 Web of Science
  • Crossref

Editorial

Liver fibrosis, cirrhosis, and portal hypertension

What we know about paracentesis induced circulatory dysfunction?
Jeong Han Kim
Clin Mol Hepatol 2015;21(4):349-351.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.349

Citations

Citations to this article as recorded by  Crossref logo
  • Serum sodium level is predictive for kidney injury or hyponatremia after modest-volume paracentesis (<5 L) in Asian patients with cirrhosis: A single-centered retrospective observational study
    Chayathorn Aramcharoen, Witchayaporn Praguylertluck, Naree Intarasak, Thanapon Yaowmaneerat, Apichat Kaewdech, Naichaya Chamroonkul, Pimsiri Sripongpun
    Medicine.2025; 104(6): e41420.     CrossRef
  • Efficacy and Safety of Ascites Treatment in Liver Cirrhosis
    G. A. Ignatenko, T. E. Kugler, G. G. Taradin, I. V. Rakitskaya, A. A. Kaluga
    Safety and Risk of Pharmacotherapy.2022; 10(2): 161.     CrossRef
  • Step by Step: Managing the Complications of Cirrhosis
    Irene Perez, Fabian J Bolte, William Bigelow, Zachary Dickson, Neeral L Shah
    Hepatic Medicine: Evidence and Research.2021; Volume 13: 45.     CrossRef
  • Current approaches to the management of patients with cirrhotic ascites
    Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev
    World Journal of Gastroenterology.2019; 25(28): 3738.     CrossRef
  • The principles of management of patients with liver cirrhosis complicated by ascites
    Dmitry V. Garbuzenko
    Clinical Medicine (Russian Journal).2017; 95(9): 789.     CrossRef
  • 12,904 View
  • 172 Download
  • 4 Web of Science
  • Crossref

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
Jun Jae Kim, Jeong Han Kim, Ja Kyung Koo, Yun Jung Choi, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol 2014;20(1):47-55.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.47
Background/Aims

The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites.

Methods

We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score.

Results

In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n=271, 51.1%), and the most common cause of death was variceal bleeding (n=20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n=115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P=0.039).

Conclusions

Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.

Citations

Citations to this article as recorded by  Crossref logo
  • Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance
    Qian-Yi Dou, Huan-Ling Guo, Wan-Bing Qiu, Ming Xu, Shu-Ling Chen, Xiao-Er Zhang, Xiao-Yan Xie, Jin-Yu Liang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis
    Alexandros Hadjivasilis, Alexander Tzanis, Kalliopi J. Ioakim, Ioanna Poupoutsi, Aris P. Agouridis, Panayiotis Kouis
    European Journal of Gastroenterology & Hepatology.2021; 33(3): 312.     CrossRef
  • Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation
    Peijie Wang, Gang Huang, Ngalei Tam, Chenglin Wu, Shunjun Fu, Bridget P. Hughes, Linwei Wu, Xiaoshun He
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1210.     CrossRef
  • 9,232 View
  • 51 Download
  • 6 Web of Science
  • Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

The lymphatic vascular system in liver diseases: its role in ascites formation
Chuhan Chung, Yasuko Iwakiri
Clin Mol Hepatol 2013;19(2):99-104.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.99

The lymphatic system is part of the circulatory system and plays a key role in normal vascular function. Its failure plays a crucial role in the development and maintenance of various diseases including liver diseases. Lymphangiogenesis (the growth of lymphatic vessels) and changes in the properties of lymphatic vessels are associated with pathogenesis of tumor metastases, ascites formation, liver fibrosis/cirrhosis and portal hypertension. Despite its significant role in liver diseases and its importance as a potential therapeutic target for those diseases, the lymphatic vascular system of the liver is poorly understood. Therefore, how the lymphatic vascular system in general and lymphangiogenesis in particular are mechanistically related to the pathogenesis and maintenance of liver diseases are largely unknown. This article summarizes: 1) the lymphatic vascular system; 2) its role in liver tumors, liver fibrosis/cirrhosis and portal hypertension; and 3) its role in ascites formation.

Citations

Citations to this article as recorded by  Crossref logo
  • Intrahepatic Lymphedema Presenting With Abnormal Bilirubin Metabolism as the Initial Manifestation
    Jingyao Li, Xiangyun Li, Jing Hao
    ACG Case Reports Journal.2026;[Epub]     CrossRef
  • Impact of nanoparticle properties on immune cell interactions in the lymph node
    Muhammad Asim Farooq, Angus P.R. Johnston, Natalie L. Trevaskis
    Acta Biomaterialia.2025; 193: 65.     CrossRef
  • Unveiling the Systemic Impact of Congestion in Heart Failure: A Narrative Review of Multisystem Pathophysiology and Clinical Implications
    Daniela Mocan, Radu Jipa, Daniel Alexandru Jipa, Radu Ioan Lala, Florin Claudiu Rasinar, Iulia Groza, Ronela Sabau, Damaris Sulea Bratu, Diana Federica Balta, Sergiu Teodor Cioban, Maria Puschita
    Journal of Cardiovascular Development and Disease.2025; 12(4): 124.     CrossRef
  • Peripheral vs. central parametric mapping of the liver in single ventricle patients: Measurement location matters
    Anna Yanovskiy, Tiina Ojala, Alma Kormi, Reetta Kivisaari, Juha Peltonen, Laura Martelius
    European Journal of Radiology.2025; 188: 112158.     CrossRef
  • The interplay between lymphatic system and portal hypertension: a comprehensive review
    Pinky Juneja, Rajni Yadav, Dinesh M. Tripathi, Savneet Kaur
    Hepatology International.2025; 19(4): 720.     CrossRef
  • Ascites – the Old, the Current, and the Future Ways of Management
    Christine Pocha, Cristian Rios-Perez
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • Portal hypertension contributes to ascites formation via the Piezo1−nuclear factor kappa-B−aquaporin1 pathway in liver cirrhosis
    Ning Wei, Li Du, Zhuanglong Xiao, Lei Zhang, Yangyang Zhou, Haonan Gao, Minghui Liu, Chengbo Wang, Xiaohua Hou, Yan Li, Yuhu Song
    Experimental & Molecular Medicine.2025; 57(10): 2305.     CrossRef
  • Risk stratification of spontaneous bacterial peritonitis recurrence: integrating acute kidney injury, biomarkers, composite scores, and machine learning models
    Nasser Mousa, Alaa Elmetwalli, Mostafa Abdelsalam, Mohamed Wahba, Mohamed Selim, Dina Nour, Eman Abdelkader, Ahmed El-Eraky, Amany Hasson, Ahmed E Taha, Eman Mousa, Adel El-Assmy, Ali El-Assmy, Sherif Shiha, Muhammad Diasty, Mohammed Abdelaziz, Shereen A.
    Gut Pathogens.2025;[Epub]     CrossRef
  • Deep brain lymphatic vessels: a new player in brain functions, neurodegenerative diseases and psychiatric disorders
    Bingqing Guo, Junzhuang Chang, Nashat Abumaria
    Stress and Brain.2024; 4(1): 46.     CrossRef
  • Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension
    Frane Pastrovic, Rudjer Novak, Ivica Grgurevic, Stela Hrkac, Grgur Salai, Marko Zarak, Lovorka Grgurevic, Sona Frankova
    PLOS ONE.2024; 19(4): e0301416.     CrossRef
  • Lymphedema in a patient with decompensated cirrhosis
    Elanaz Alizade, Muhsin Murat Harputluoğlu, Ali Alizade
    Annals of Innovation in Medicine.2024;[Epub]     CrossRef
  • Single-Center Experience With Dynamic Contrast-Enhanced Magnetic Resonance Lymphangiography for Diagnosing Lymphatic Disorders and Guiding Percutaneous Embolization
    Yura Ahn, Hyun Jung Koo, Jooae Choe, Hee Ho Chu, Dong Hyun Yang, Joon-Won Kang, Ji Hoon Shin
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Lymphatic System Development and Function
    Harish P. Janardhan, Brianna T. Wachter, Chinmay M. Trivedi
    Current Cardiology Reports.2024; 26(11): 1209.     CrossRef
  • Lymphangiogenesis in the liver of biliary atresia
    Seitaro Kosaka, Toshihiro Muraji, Haruo Ohtani, Toshio Harumatsu, Sakika Shimizu, Miki Toma, Toshihiro Yanai, Satoshi Ieiri
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • The ebb and flow of cardiac lymphatics: a tidal wave of new discoveries
    Natalie R. Harris, László Bálint, Danielle M. Dy, Natalie R. Nielsen, Hernán G. Méndez, Amir Aghajanian, Kathleen M. Caron
    Physiological Reviews.2023; 103(1): 391.     CrossRef
  • Clinical anatomy of hepatic vessels by computed tomography angiography: A minireview
    Aysegul Firat, Tugce Taskindere Abbasoglu, Musturay Karcaaltincaba, Yasemin H Balaban
    World Journal of Radiology.2023; 15(1): 1.     CrossRef
  • Fontan-associated liver disease: Diagnosis, surveillance, and management
    Charlotte de Lange, Thomas Möller, Hanna Hebelka
    Frontiers in Pediatrics.2023;[Epub]     CrossRef
  • Lymphatics in the liver for translational science
    Yasuko Iwakiri
    Clinical Liver Disease.2023; 21(4): 122.     CrossRef
  • Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis
    Pinky Juneja, Syed Nazrin Ruhina Rahman, Deepika Jakhar, Akash Kumar Mourya, Dinesh M. Tripathi, Impreet Kaur, Vaibhav Tiwari, Sumati Rohilla, Abhishek Gupta, Preety Rawal, Sukriti Baweja, Archana Rastogi, V.G.M. Naidu, Shiv K. Sarin, Subham Banerjee, Sav
    JHEP Reports.2023; 5(10): 100816.     CrossRef
  • Lymphatic vasculature in ovarian cancer
    Sarit Pal, Sramana Bhowmick, Anurag Sharma, Jorge A. Sierra-Fonseca, Susmita Mondal, Favour Afolabi, Debarshi Roy
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(5): 188950.     CrossRef
  • Oxidative Stress–Induced Liver Damage and Remodeling of the Liver Vasculature
    Priyanka Banerjee, Niyanshi Gaddam, Vanessa Chandler, Sanjukta Chakraborty
    The American Journal of Pathology.2023; 193(10): 1400.     CrossRef
  • Lymphatic drainage dysfunction via narrowing of the lumen of cisterna chyli and thoracic duct after luminal dilation
    Ryo Yano, Masashi Hirooka, Yohei Koizumi, Yoshiko Nakamura, Yusuke Imai, Makoto Morita, Yuki Okazaki, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
    Hepatology International.2023; 17(6): 1557.     CrossRef
  • An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver
    Jain Jeong, Masatake Tanaka, Yilin Yang, Nikolai Arefyev, Jenna DiRito, Gregory Tietjen, Xuchen Zhang, Matthew J. McConnell, Teruo Utsumi, Yasuko Iwakiri
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2023; 325(5): G379.     CrossRef
  • Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism
    Rahul Arya, Ramesh Kumar, Tarun Kumar, Sudhir Kumar, Utpal Anand, Rajeev Nayan Priyadarshi, Tanmoy Maji
    World Journal of Hepatology.2023; 15(10): 1140.     CrossRef
  • Hepatic lymphatic vascular system in health and disease
    Jain Jeong, Masatake Tanaka, Yasuko Iwakiri
    Journal of Hepatology.2022; 77(1): 206.     CrossRef
  • A classification of abdominal lymphatic perfusion patterns after Fontan surgery
    Christian Schroeder, Julia Moosmann, Robert Cesnjevar, Ariawan Purbojo, Oliver Rompel, Sven Dittrich
    European Journal of Cardio-Thoracic Surgery.2022;[Epub]     CrossRef
  • Serial T2-Weighted Thoracic and Abdominal Lymphatic Imaging in Fontan Patients—New Insights into Dynamics of Lymphatic Abnormalities after Total Cavopulmonary Connection
    Julia Moosmann, Christian Schroeder, Oliver Rompel, Ariawan Purbojo, Sven Dittrich
    Journal of Cardiovascular Development and Disease.2022; 9(5): 138.     CrossRef
  • Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
    Masashi Hirooka, Yohei Koizumi, Ryo Yano, Yoshiko Nakamura, Koutarou Sunago, Atsushi Yukimoto, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
    Scientific Reports.2022;[Epub]     CrossRef
  • A Metabolomic Analysis of Cirrhotic Ascites
    Diren Beyoğlu, Cedric Simillion, Federico Storni, Andrea De Gottardi, Jeffrey R. Idle
    Molecules.2022; 27(12): 3935.     CrossRef
  • Paneth Cells Regulate Lymphangiogenesis under Control of Microbial Signals during Experimental Portal Hypertension
    Mohsin Hassan, Oriol Juanola, Irene Keller, Paolo Nanni, Witold Wolski, Sebastián Martínez-López, Esther Caparrós, Rubén Francés, Sheida Moghadamrad
    Biomedicines.2022; 10(7): 1503.     CrossRef
  • Oxidized low density lipoprotein in the liver causes decreased permeability of liver lymphatic- but not liver sinusoidal-endothelial cells via VEGFR-3 regulation of VE-Cadherin
    Alyssa R. Goldberg, Megan Ferguson, Sarit Pal, Rachel Cohen, David J. Orlicky, Rebecca L. McCullough, Joseph M. Rutkowski, Matthew A. Burchill, Beth A. Jirón Tamburini
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Abdominal lymphatic system visibility, morphology, and abnormalities in children as seen on routine MCRP and its association with immune-mediated diseases
    Ebtehaj AlShehri, Christopher Z. Lam, Binita M. Kamath, Govind B. Chavhan
    European Radiology.2021; 31(1): 292.     CrossRef
  • Potential of Liver T1 Mapping for the Detection of Fontan-associated Liver Disease in Adults
    Yumi Shiina, Kei Inai, Ryoko Ohashi, Michinobu Nagao
    Magnetic Resonance in Medical Sciences.2021; 20(3): 295.     CrossRef
  • Dieckol Decreases Caloric Intake and Attenuates Nonalcoholic Fatty Liver Disease and Hepatic Lymphatic Vessel Dysfunction in High-Fat-Diet-Fed Mice
    Kyung-A Byun, Seyeon Oh, Myeongjoo Son, Chul-Hyun Park, Kuk Hui Son, Kyunghee Byun
    Marine Drugs.2021; 19(9): 495.     CrossRef
  • Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications
    Ramesh Kumar, Utpal Anand, Rajeev Nayan Priyadarshi
    World Journal of Hepatology.2021; 13(3): 300.     CrossRef
  • Pathophysiology of the Lymphatic System in Patients With Heart Failure
    Maxim Itkin, Stanley G. Rockson, Daniel Burkhoff
    Journal of the American College of Cardiology.2021; 78(3): 278.     CrossRef
  • The Relationship Between Lymphangiogenesis and Liver Regeneration After Partial Hepatectomy in Cholestatic Mice
    Takashi Hamada, Masaaki Hidaka, Mitsuhisa Takatsuki, Yusuke Sakai, Haung Yu, Koji Natsuda, Shinichiro Ono, Tomohiko Adachi, Akihiko Soyama, Susumu Eguchi
    Lymphatic Research and Biology.2020; 18(4): 322.     CrossRef
  • The Role of Lymphatic Vascular Function in Metabolic Disorders
    Pieter R. Norden, Tsutomu Kume
    Frontiers in Physiology.2020;[Epub]     CrossRef
  • Lymphatic targeting by albumin-hitchhiking: Applications and optimisation
    Mohammad Abdallah, Olivia O. Müllertz, Ian K. Styles, Alexander Mörsdorf, John F. Quinn, Michael R. Whittaker, Natalie L. Trevaskis
    Journal of Controlled Release.2020; 327: 117.     CrossRef
  • The lymphatic system in alcohol-associated liver disease
    Reiichiro Kondo, Yasuko Iwakiri
    Clinical and Molecular Hepatology.2020; 26(4): 633.     CrossRef
  • Liver lymphatic drainage patterns follow segmental anatomy in a murine model
    Nicola C. Frenkel, Susanna Poghosyan, André Verheem, Timothy P. Padera, Inne H. M. Borel Rinkes, Onno Kranenburg, Jeroen Hagendoorn
    Scientific Reports.2020;[Epub]     CrossRef
  • Imaging the Lymphatic System in Fontan Patients
    Floris E.A. Udink ten Cate, Eric T.T.L. Tjwa
    Circulation: Cardiovascular Imaging.2019;[Epub]     CrossRef
  • Non-contrast MR lymphography of the lymphatic system of the liver
    Lionel Arrivé, Laurence Monnier-Cholley, Nora Cazzagon, Dominique Wendum, Edouard Chambenois, Sanaâ El Mouhadi
    European Radiology.2019; 29(11): 5879.     CrossRef
  • Fontan-associated liver disease: A review
    Timothy T. Gordon-Walker, Kevin Bove, Gruschen Veldtman
    Journal of Cardiology.2019; 74(3): 223.     CrossRef
  • Chronic Liver Disease in Humans Causes Expansion and Differentiation of Liver Lymphatic Endothelial Cells
    Beth A. Jiron Tamburini, Jeffrey M. Finlon, Austin E. Gillen, Michael S. Kriss, Kent A. Riemondy, Rui Fu, Ronald P. Schuyler, Jay R. Hesselberth, Hugo R. Rosen, Matthew A. Burchill
    Frontiers in Immunology.2019;[Epub]     CrossRef
  • The Role of Hepatic and Splanchnic Lymphatic System in Portal Hypertension and Ascites
    Jordi Ribera, Bernat Córdoba-Jover, Irene Portolés, Manuel Morales-Ruiz
    Current Hepatology Reports.2019; 18(2): 157.     CrossRef
  • Nanoparticles' interactions with vasculature in diseases
    Jie Kai Tee, Li Xian Yip, Eveline Sheau Tan, Supawan Santitewagun, Arun Prasath, Pu Chun Ke, Han Kiat Ho, David Tai Leong
    Chemical Society Reviews.2019; 48(21): 5381.     CrossRef
  • Metabolism in Acute-On-Chronic Liver Failure: The Solution More than the Problem
    Maria-Angeles Aller, Natalia Arias, Javier Blanco-Rivero, Jaime Arias
    Archives of Medical Research.2019; 50(5): 271.     CrossRef
  • Biology of portal hypertension
    Matthew McConnell, Yasuko Iwakiri
    Hepatology International.2018; 12(S1): 11.     CrossRef
  • Modern Techniques of Lymphangiography and Interventions: Current Status and Future Development
    Maxim Itkin, Gregory J. Nadolski
    CardioVascular and Interventional Radiology.2018; 41(3): 366.     CrossRef
  • Emerging Concepts in Organ-Specific Lymphatic Vessels and Metabolic Regulation of Lymphatic Development
    Brian W. Wong, Annalisa Zecchin, Melissa García-Caballero, Peter Carmeliet
    Developmental Cell.2018; 45(3): 289.     CrossRef
  • Lymphatics in the liver
    Masatake Tanaka, Yasuko Iwakiri
    Current Opinion in Immunology.2018; 53: 137.     CrossRef
  • Risk Factors for Intractable Ascites After Adult-to-Adult Living Donor Liver Transplantation Using Left Lobe
    Shinichi Matsudaira, Yoichi Ishizaki, Jiro Yoshimoto, Noriko Fujiwara, Seiji Kawasaki
    Transplantation Direct.2017; 3(3): e138.     CrossRef
  • Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD
    Sarah Mertlitz, Yu Shi, Martina Kalupa, Carsten Grötzinger, Jörg Mengwasser, Katarina Riesner, Steffen Cordes, Sefer Elezkurtaj, Olaf Penack
    Blood.2017; 129(13): 1865.     CrossRef
  • Periportal lymphatic system on post-hepatobiliary phase Gd-EOB-DTPA-enhanced MR imaging in normal subjects and patients with chronic hepatitis C
    Yasunari Yamada, Shunro Matsumoto, Hiromu Mori, Ryo Takaji, Maki Kiyonaga, Naoki Hijiya, Rika Tanoue, Kenichiro Tomonari, Shuichi Tanoue, Norio Hongo, Masayuki Ohta, Masataka Seike, Masafumi Inomata, Kazunari Murakami, Masatsugu Moriyama
    Abdominal Radiology.2017; 42(10): 2410.     CrossRef
  • MR lymphography of hepatic lymphatic system
    Lionel Arrivé, Sanaâ El Mouhadi
    Hepatology.2017; 65(6): 2132.     CrossRef
  • Reply
    Yasuko Iwakiri
    Hepatology.2017; 65(6): 2134.     CrossRef
  • The Lymphatic System: The Achilles Heel of the Fontan-Kreutzer Circulation
    Christian Kreutzer, Guillermo Kreutzer
    World Journal for Pediatric and Congenital Heart Surgery.2017; 8(5): 613.     CrossRef
  • Anti-angiogenic and anti-lymphangiogenic role of praziquantel and artemether in experimental mansoniasis
    Naglaa Fathy Abd El-Aal, Rania Said Hamza, Mona Magdy
    Acta Parasitologica.2017;[Epub]     CrossRef
  • Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases
    Florent Duval, Delia Elva Cruz-Vega, Ivonne González-Gamboa, María Teresa González-Garza, Fernando Ponz, Flora Sánchez, Gabriela Alarcón-Galván, Jorge E. Moreno-Cuevas
    Disease Markers.2016; 2016: 1.     CrossRef
  • Functional Immune Anatomy of the Liver—As an Allograft
    A.J. Demetris, C.O.C. Bellamy, C.R. Gandhi, S. Prost, Y. Nakanuma, D.B. Stolz
    American Journal of Transplantation.2016; 16(6): 1653.     CrossRef
  • The lymphatic system: A new frontier in hepatology
    Yasuko Iwakiri
    Hepatology.2016; 64(3): 706.     CrossRef
  • Anatomy of hepatic lymphatics and its implications in hepatic malignancies
    Tuck Leong Yong, Nezor Houli, Chris Christophi
    ANZ Journal of Surgery.2016; 86(11): 868.     CrossRef
  • The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis
    Masatake Tanaka, Yasuko Iwakiri
    Cellular and Molecular Gastroenterology and Hepatology.2016; 2(6): 733.     CrossRef
  • Importance Rat Liver Morphology and Vasculature in Surgical Research
    Katarína Vdoviaková, Katarína Vdoviaková, Eva Petrovová, Lenka Krešáková, Marcela Maloveská, Jana Teleky, Janka Jenčová, Jozef Živčák, Andrej Jenča Jr.
    Medical Science Monitor.2016; 22: 4716.     CrossRef
  • Avicenna (980-1037) on the Role of the Liver in Separating Fluid from the Blood, with Insight into the Process from E.H. Starling (1866-1907) a Millennium Later
    Leon G. Fine
    Nephron.2016; 133(2): 139.     CrossRef
  • The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics
    Yuji Morine, Mitsuo Shimada
    Journal of Gastroenterology.2015; 50(9): 913.     CrossRef
  • Nitric oxide in liver diseases
    Yasuko Iwakiri, Moon Young Kim
    Trends in Pharmacological Sciences.2015; 36(8): 524.     CrossRef
  • Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions
    Yasuko Iwakiri, Vijay Shah, Don C. Rockey
    Journal of Hepatology.2014; 61(4): 912.     CrossRef
  • Pathophysiology of Portal Hypertension
    Yasuko Iwakiri
    Clinics in Liver Disease.2014; 18(2): 281.     CrossRef
  • Formation of Fenestrae in Murine Liver Sinusoids Depends on Plasmalemma Vesicle-Associated Protein and Is Required for Lipoprotein Passage
    Leonie Herrnberger, Robert Hennig, Werner Kremer, Claus Hellerbrand, Achim Goepferich, Hans Robert Kalbitzer, Ernst R. Tamm, Rafael Aldabe
    PLoS ONE.2014; 9(12): e115005.     CrossRef
  • Effects of Adenosine on Lymphangiogenesis
    Bénédicte Lenoir, Daniel R. Wagner, Silvia Blacher, Graciela B. Sala-Newby, Andrew C. Newby, Agnès Noel, Yvan Devaux, Philippe Rouet
    PLoS ONE.2014; 9(3): e92715.     CrossRef
  • Update December 2013
    Francine Blei
    Lymphatic Research and Biology.2013; 11(4): 239.     CrossRef
  • 14,557 View
  • 248 Download
  • 72 Web of Science
  • Crossref

Original Articles

Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels
Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Korean J Hepatol 2011;17(2):130-138.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.130
Background/Aims

Several studies suggested that serum cystatin C (CysC) is more useful than serum creatinine (Cr) for the assessment of renal function in patients with liver cirrhosis. This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and normal Cr level.

Methods

We enrolled patients with cirrhotic ascites and a normal serum Cr level (<1.2 mg/dL). GFR was measured by 99mTc-DTPA renal scan. Serum Cr, CysC, and Cr clearance (CCr) were measured on the same day. Significant renal impairment and severe renal impairment were defined as GFR <60 mL/min and GFR <30 mL/min, respectively.

Results

Eighty-nine patients with cirrhotic ascites were enrolled in the study (63 men and 26 women; age, 55±11 years). Forty-seven (52.8%) and 42 (47.2%) patients were in Child-Pugh grade B and C, respectively. Serum Cr and CysC levels and GFR were 0.8±0.2 mg/dL, 1.1±0.3 mg/L, and 73.4±25.5 mL/min, respectively. Significant and severe renal impairment were noted in 28 (31.5%) and 2 (2.2%) patients, respectively. GFR was well correlated with serum Cr, CysC, and e-GFRMDRD, while it was not correlated with e-GFRC&G. In multivariate analysis, only CysC was significantly correlated with GFR (β, 45.620; 95% CI, 23.042-68.198; P<0.001). Serum CysC level was the only independent predictor for significant renal impairment.

Conclusions

Significant renal dysfunction was not rare in patients with cirrhotic ascites, even their serum Cr level is normal. Serum CysC is a useful marker for detecting significant renal dysfunction in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Diagnostic value of serum TGF-β1 and CysC in type 2 diabetic kidney disease: a cross-sectional study
    Yi Kang, Qian Jin, Mengqi Zhou, Huijuan Zheng, Xiaobin Li, Aoshuang Li, Jing Wei Zhou, Jie Lv, Yaoxian Wang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Zonula occludens 1 as a novel biomarker in decompensated alcoholic cirrhosis with hepatorenal syndrome
    Balasubramaniyan Vairappan, Raj Kumar, Mukta Wyawahare
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Improved outcomes of kidney after liver transplantation after the implementation of the safety net policy
    Rose Mary Attieh, Ramez M. Ibrahim, Peter Ghali, Andrew Keaveny, Kristopher Croome, David Hodge, Launia White, Hani M. Wadei
    Liver Transplantation.2024; 30(6): 582.     CrossRef
  • The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury
    Ahmed M. Abd El Wahab, Abeer Awadeen, Mostafa M. Mansour, Rasha Shemies
    Therapeutic Apheresis and Dialysis.2023; 27(3): 419.     CrossRef
  • Role of Novel Kidney Biomarkers in Patients With Cirrhosis and After Liver Transplantation
    Sumeet K. Asrani, Nagasri Shankar, Briget da Graca, Mitra K. Nadim, Andres Cardenas
    Liver Transplantation.2022; 28(3): 466.     CrossRef
  • Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
    Fathia Elsayed Asal, Mohamed Yousef, Hend Atteya Abdelkhalek Abdraboh, Sherief Abd-Elsalam, Ahmed Abdelaziz Abdelaziz Shama, Mohamed Elbahnasawy, Mohammed H Elnaggar, Hesham Ahmed Alsrogy, Heba Elashry
    The Open Biomarkers Journal.2022;[Epub]     CrossRef
  • Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis
    Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani
    Liver Transplantation.2021; 27(11): 1538.     CrossRef
  • Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure
    Praveen Jha, Ashish Kumar Jha, Vishwa Mohan Dayal, Sanjeev Kumar Jha, Amarendra Kumar
    Indian Journal of Gastroenterology.2021; 40(6): 563.     CrossRef
  • Serum cystatin C unmasks renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate
    Balaraman Velayudham, RemiGeorge Thomas, C Vasudevan, RP Senthilkumar, Thirumalvalavan, Murugesan
    Saudi Journal of Kidney Diseases and Transplantation.2020; 31(6): 1320.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients
    Dong Wang, Jia-Fu Feng, An-Qun Wang, Yu-Wei Yang, Yun-Shuang Liu
    Medicine.2017; 96(20): e6949.     CrossRef
  • How to evaluate renal function in stable cirrhotic patients
    Florencia I. Aiello, Magdalena Bajo, Fernanda Marti, Carlos G. Musso
    Postgraduate Medicine.2017; 129(8): 866.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis
    Mahmoud Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat Assem, Gasser El-Azab
    International Journal of Hepatology.2015; 2015: 1.     CrossRef
  • GFR Estimating Equations and Liver Disease
    Tomasz Beben, Dena E. Rifkin
    Advances in Chronic Kidney Disease.2015; 22(5): 337.     CrossRef
  • Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine
    Bilyana Teneva, Emiliya Karaslavova
    Open Medicine.2014; 9(5): 625.     CrossRef
  • Update on Cystatin C: Incorporation Into Clinical Practice
    Michael G. Shlipak, Monica D. Mattes, Carmen A. Peralta
    American Journal of Kidney Diseases.2013; 62(3): 595.     CrossRef
  • Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation
    Jeffrey C Sirota, Angela Walcher, Sarah Faubel, Alkesh Jani, Kim McFann, Prasad Devarajan, Connie L Davis, Charles L Edelstein
    BMC Nephrology.2013;[Epub]     CrossRef
  • Impact of creatinine production on the agreement between glomerular filtration rate estimates using cystatin C-derived, and 4- and 6-variable Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equ
    Esperanza F. Hermida-Cadahia, Natalia Lampon, J. Carlos Tutor
    Upsala Journal of Medical Sciences.2012; 117(4): 402.     CrossRef
  • Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury
    W. Stephen Waring, Alasdair Moonie
    Clinical Toxicology.2011; 49(8): 720.     CrossRef
  • 12,585 View
  • 89 Download
  • Crossref
Diagnostic usefulness of the random urine Na/K ratio in cirrhotic patients with ascites: a pilot study
Jae Eun Park, M.D., Chang Hyeong Lee, M.D., Byung Seok Kim, M.D., Im Hee Shin, Ph.D.1
Korean J Hepatol 2010;16(1):66-74.
Published online March 26, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.1.66
Background/Aims
Twenty-four hour urinary sodium excretion (24-h UNa) of greater than 78 mmol/day is important in the management of cirrhotic ascites. Although the random urine sodium-to-potassium ratio (UNa/K) is strongly correlated with 24-h UNa, and approximately 95% of patients with a random UNa/K greater than 1 have 24-h UNa greater than 78mmol, few data have been published on the correlation between 24-h UNa and random UNa/K. We evaluated diagnostic value of morning and afternoon random UNa/K (AM UNa/K and PM UNa/K, respectively) with 24-h UNa. Methods: A total of 42 male patients were enrolled from October 2007 to March 2008. Each patient collected 5 mL of urine twice at random times during 24-h urine collection (at 10-12 a.m. and 3-5 p.m.). ROC curve analysis was performed to evaluate the feasibility of AM and PM UNa/K for differentiating 24-h UNa greater than 78mmol/day. Results: Forty patients with a 24-h urinary creatinine of greater than 15 mg/kg were analyzed. The 24-h UNa, AM UNa/K, and PM UNa/K were 107.9±91.2mmol (mean±SD), 3.44±3.64, and 3.97±4.60, respectively. When compared with 24-h UNa greater than 78 mmol, AUROC values for AM and PM UNa/K were 0.861 (95% CI, 0.715-0.950) and 0.929 (95% CI, 0.802-0.986), respectively (P=0.0001). No difference was found between the AUROC for AM and PM UNa/K (95% CI, -0.161-0.153, P=0.113). UNa/K greater than 1.25 was sensitive and specific for prediction of 24-h UNa greater than 78 mmol. Conclusions: The results suggest that anytime random UNa/K greater than 1.25 is an accurate, cost-effective, and convenient method for replacing 24-h UNa. Large multicentered cohort studies are needed to confirm our results. (Korean J Hepatol 2010; 16:66-74)

Citations

Citations to this article as recorded by  Crossref logo
  • Evaluations of Surface PM10 Concentration and Chemical Compositions in MERRA-2 Aerosol Reanalysis over Central and Eastern China
    Xiaodan Ma, Peng Yan, Tianliang Zhao, Xiaofang Jia, Jian Jiao, Qianli Ma, Dongqiao Wu, Zhuozhi Shu, Xiaoyun Sun, Birhanu Asmerom Habtemicheal
    Remote Sensing.2021; 13(7): 1317.     CrossRef
  • Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites
    Jin Wook Lee, Jae Seok Hwang, Woo Jin Chung, Heon Ju Lee, Jung Gil Park, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Byoung Kuk Jang, Bhagwan Dass
    PLOS ONE.2021; 16(6): e0253886.     CrossRef
  • Low sodium to potassium ratio in spot urine sample is associated with progression to acute kidney injury and mortality in hospitalized patients with cirrhosis
    Elayne Cristina Morais Rateke, Camila Matiollo, Emerita Quintina de Andrade Moura, Michelle Andrigueti, Claudia Maccali, Janaína Sant'Ana Fonseca, Sabine Machado Fiorenza Canova, Janaína Luz Narciso-Schiavon, Leonardo Lucca Schiavon
    Digestive and Liver Disease.2021; 53(9): 1159.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Comparative study of spot urine Na/K ratio and 24-hour urine sodium in natriuresis evaluation of cirrhotic patients with ascites
    Otávio Marcos da Silva, Gabriela Bicca Thiele, Leonardo Fayad, César Lazzarotto, Esther Buzaglo Dantas-Corrêa, Leonardo de Lucca Schiavon, Janaína Luz Narciso-Schiavon
    GE Jornal Português de Gastrenterologia.2014; 21(1): 15.     CrossRef
  • Avaliação da natriurese no doente cirrótico: determinação pontual Na+/K+na urina ou doseamento de sódio na urina de 24 horas?
    Susana Lopes
    GE Jornal Português de Gastrenterologia.2014; 21(1): 7.     CrossRef
  • Can 24‐h urine sodium excretion be replaced by spot urine sodium/potassium in patients with decompensated cirrhosis?
    Evangelos Cholongitas, Stylianos Karatapanis, Theodora Nakouti, Charis Birtsou, Labrini Skorda, Ioannis Kouvelis, Vasilios Papastergiou, Nikolaos Papachrysos, John Goulis, Evangelos Akriviadis
    Liver International.2012; 32(1): 172.     CrossRef
  • 5,924 View
  • 101 Download
  • Crossref

Editorial

Citations

Citations to this article as recorded by  Crossref logo
  • AGA Clinical Practice Update on Interventional EUS for Vascular Investigation and Therapy: Commentary
    Marvin Ryou, John M. DeWitt, Koushik K. Das, Vanessa M. Shami
    Clinical Gastroenterology and Hepatology.2023; 21(7): 1699.     CrossRef
  • Evolution of interventional endoscopic ultrasound
    Mark J Radlinski, Daniel S Strand, Vanessa M Shami
    Gastroenterology Report.2022;[Epub]     CrossRef
  • Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea
    Jin Nyoung Kim, Kyoung Min Sohn, Moon Young Kim, Ki Tae Suk, Soung Won Jeong, Ho Eun Jung, Sae Hwan Lee, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Hong Soo Kim, Dong Joon Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2012; 18(4): 391.     CrossRef
  • 5,409 View
  • 23 Download
  • Crossref

Original Article

Changes in the Profiles of Causative Agents and Antibiotic Resistance Rate for Spontaneous Bacterial Peritonitis: an Analysis of Cultured Microorganisms in Recent 12 Years
Moon Kyung Park , Joon Hyoek Lee , Young Hye Byun , Hyang Ie Lee , Geum Youn Gwak , Moon Seok Choi , Kwang Cheol Koh , Seung Woon Paik , Byung Chol Yoo , Jong Chol Rhee
Korean J Hepatol 2007;13(3):370-377.
Published online September 20, 2007
DOI: https://doi.org/10.3350/kjhep.2007.13.3.370
Backgrounds/Aims: The causative agents for spontaneous bacterial peritonitis (SBP) and antibiotic resistance rate vary according to the regions and time. This study evaluated the recent changes in the profiles of microorganisms and antibiotic resistance rate for the choice of effective antibiotics in treating SBP. Methods: The clinical records of 1,018 episodes of SBP from November, 1994 to December, 2005, were analyzed retrospectively. The profiles of the causative agents for SBP and the rate of antibiotic resistance were compared in every 4-year-term. Results: The microorganisms were isolated in 394 out of 1018 episodes (38.7%). Gram negative and positive organisms constituted 71.6% and 21.3%, respectively. The five most commonly isolated organisms were E. coli (35.8%), K. pneumoniae (15.5%), viridans Streptococci (10.4%), S. pneumoniae (4.8%) and Aeromonas group (4.6%). The rate of E. coli resistant to cefotaxime (0%, 5.4%, 7.4%) and ciprofloxacin (4.3%, 21.6%, 28.4%) were increased in recent years. In the gram positive organisms, all isolates of viridans Streptococci and Pneumococci were sensitive to cefotaxime and ciprofloxacin. Recently, methicillin-resistant Staphylococcus aureus (MRSA) (28%) and vancomycin-resistant Enterococci (VRE) (31%) have been isolated. In each period, the overall antibiotic resistance rates to cefotaxime were 12.5%, 14.0%, 14.8%, to ciprofloxacin were 3.1%, 16.7%, 18.0%, and to imipenem were 4.7%, 7.0%, 4.2%. Conclusions: Cefotaxime may still be the choice of primary empirical antibiotics for the treatment of SBP in Korea because the rate of resistance is acceptable. However, it is important to be aware of the recent increase in ciprofloxacin-resistant E. coli, extended spectrum beta-lactamase (ESBL)-producing gram negative bacilli, MRSA and VRE. (Korean J Hepatol 2007;13:370-377)

Citations

Citations to this article as recorded by  Crossref logo
  • Effect of acute kidney injury on long‐term outcomes of spontaneous bacterial peritonitis in cirrhotic patients using the International Club of Ascites‐acute kidney injury criteria
    Won Sohn, Jung Hee Kim, Ju‐Yeon Cho
    Journal of Gastroenterology and Hepatology.2020; 35(5): 870.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Spontaneous Bacterial Peritonitis
    Do Seon Song
    The Korean Journal of Gastroenterology.2018; 72(2): 56.     CrossRef
  • Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
    Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites
    Sun Hee Na, Eun Jung Kim, Eun Young Nam, Kyoung-Ho Song, Pyoeng Gyun Choe, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Sang Won Park, Hong Bin Kim, Myoung-don Oh, Nam Joong Kim
    Scandinavian Journal of Gastroenterology.2017; 52(2): 199.     CrossRef
  • Do We Need to Change the Treatment Strategy for Spontaneous Bacterial Peritonitis in Patients with Advanced Cirrhosis?
    Chang Wook Kim
    The Korean Journal of Gastroenterology.2017; 69(2): 93.     CrossRef
  • Clinical Features of Spontaneous Bacterial Peritonitis: A 10-year Experience from a Single Center
    Ha Young Na, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    The Korean Journal of Gastroenterology.2017; 69(2): 129.     CrossRef
  • Appropriateness of antibiotic usage for gastrointestinal disorders in a tertiary care hospital
    Gayathri Madhu S, Emmanuel James, Rama P Venu
    European Journal of Hospital Pharmacy.2016; 23(5): 283.     CrossRef
  • Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients
    Yong-Tao Li
    World Journal of Gastroenterology.2015; 21(36): 10409.     CrossRef
  • A Case of Spontaneous Bacterial Peritonitis Following Argon Plasma Coagulation for Angiodysplasias in the Colon
    Hye Jin Jung, Soo Hyung Ryu, Kyoung Sik Park, Won Jae Yoon, Jin Nam Kim, You Sun Kim, Jeong Seop Moon
    The Korean Journal of Gastroenterology.2014; 64(2): 115.     CrossRef
  • Patterns of Antimicrobial Resistance in the Causative Organisms of Spontaneous Bacterial Peritonitis: A Single Centre, Six-Year Experience of 1981 Samples
    Sara Sheikhbahaei, Alireza Abdollahi, Nima Hafezi-Nejad, Elham Zare
    International Journal of Hepatology.2014; 2014: 1.     CrossRef
  • Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: a retrospective cohort study
    Min Jae Kim, Kyoung-Ho Song, Nak-Hyun Kim, Pyoeng Gyun Choe, Wan Beom Park, Ji Hwan Bang, Eu Suk Kim, Sang Won Park, Hong Bin Kim, Hyo-Suk Lee, Myoung-don Oh, Nam Joong Kim
    Hepatology International.2014; 8(4): 582.     CrossRef
  • Etiology and Antimicrobial Susceptibility Profile of Isolates from Ascitic Fluid of Patients with Spontaneous Bacterial Peritonitis
    Veenu Gupta, Rajoo Singh Chhina, Jyoti Chaudhary, Manisha Aggarwal, Priyam Chawla, Deepinder Kaur
    Journal of Gastrointestinal Infections.2014; 4(1): 47.     CrossRef
  • Identification of Bacterial Pathogens and their Antibiogram from Ascitic Fluid in a Rural Tertiary Care Hospital of North India
    Anuradha Sood, Kamlesh Thakur, Subhash Chand Jaryal, Puneet Kumar Gupta, Smriti Chauhan
    Journal of Gastrointestinal Infections.2014; 4(1): 19.     CrossRef
  • Etiology and Antimicrobial Susceptibility Profile of Isolates from Ascitic Fluid of Patients with Spontaneous Bacterial Peritonitis
    Veenu Gupta, Rajoo Singh Chhina, Jyoti Chaudhary, Manisha Aggarwal, Priyam Chawla, Deepinder Kaur
    Journal of Gastrointestinal Infections.2014; 4(1): 47.     CrossRef
  • Identification of Bacterial Pathogens and their Antibiogram from Ascitic Fluid in a Rural Tertiary Care Hospital of North India
    Anuradha Sood, Kamlesh Thakur, Subhash Chand Jaryal, Puneet Kumar Gupta, Smriti Chauhan
    Journal of Gastrointestinal Infections.2014; 4(1): 19.     CrossRef
  • Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis
    Pei Chuan Tsung, Soo Hyung Ryu, In Hye Cha, Hee Won Cho, Jin Nam Kim, You Sun Kim, Jeong Seop Moon
    Clinical and Molecular Hepatology.2013; 19(2): 131.     CrossRef
  • Role of ascitic fluid C3 in spontaneous bacterial peritonitis
    Amany Talaat Kamal, Eman Nagib Osman, Rasha Youssef Shahin
    Egyptian Journal of Medical Human Genetics.2012; 13(1): 81.     CrossRef
  • First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage
    Srdan Novovic, Synne Semb, Henrik Olsen, Claus Moser, Jenny Dahl Knudsen, Christian Homann
    Scandinavian Journal of Gastroenterology.2012; 47(2): 212.     CrossRef
  • Prevalence of spontaneous bacterial peritonitis in asymptomatic inpatients with decompensated liver cirrhosis – a pilot study
    B Kasztelan – Szczerbinska, M Słomka, K Celinski, M Serwacki, M Szczerbinski, H Cichoz- Lach
    Advances in Medical Sciences.2011; 56(1): 13.     CrossRef
  • Routine analysis of cirrhotic ascites for evidence of infection – not worth the effort?
    Varghese Thomas
    Indian Journal of Gastroenterology.2011; 30(5): 201.     CrossRef
  • Immune Dysfunction and Infections in Patients With Cirrhosis
    Alexander R. Bonnel, Chalermrat Bunchorntavakul, K. Rajender Reddy
    Clinical Gastroenterology and Hepatology.2011; 9(9): 727.     CrossRef
  • Current status of liver diseases in Korea: Liver cirrhosis
    Jeong Won Jang
    The Korean Journal of Hepatology.2009; 15(Suppl 6): S40.     CrossRef
  • Bacterial epidemiology and antimicrobial resistance in ascitic fluid: A 2-year retrospective study
    Lionel Piroth, André Pechinot, Anne Minello, Benoit Jaulhac, Isabelle Patry, Tahar Hadou, Yves Hansmann, Christian Rabaud, Pascal Chavanet, Catherine Neuwirth
    Scandinavian Journal of Infectious Diseases.2009; 41(11-12): 847.     CrossRef
  • Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction
    Tony Bruns, Svea Sachse, Eberhard Straube, Sentayehu Assefa, Andreas Herrmann, Stefan Hagel, Marc Lehmann, Andreas Stallmach
    Liver International.2009; 29(8): 1206.     CrossRef
  • Microbiological Characteristics of Spontaneous Bacterial Peritonitis in Korea
    Jeong Heo, Soon Ho Um
    The Korean Journal of Hepatology.2007; 13(3): 304.     CrossRef
  • 5,716 View
  • 49 Download
  • Crossref

Editorial

Microbiological Characteristics of Spontaneous Bacterial Peritonitis in Korea
Jeong Heo, M.D., Soon Ho Um, M.D.1
Korean J Hepatol 2007;13(3):304-308.
Published online September 20, 2007
DOI: https://doi.org/10.3350/kjhep.2007.13.3.304

Citations

Citations to this article as recorded by  Crossref logo
  • A Case of Peritoneal Dialysis-related Peritonitis Caused by Aeromonas Hydrophila in the Patient Receiving Automated Peritoneal Dialysis
    Hyun Jin Kim, Hyun Sun Park, Eunsin Bae, Hae Won Kim, Beom Kim, Kyoung Hyoub Moon, Dong-Young Lee
    Electrolytes & Blood Pressure.2018; 16(2): 27.     CrossRef
  • Current status of liver diseases in Korea: Liver cirrhosis
    Jeong Won Jang
    The Korean Journal of Hepatology.2009; 15(Suppl 6): S40.     CrossRef
  • 5,574 View
  • 28 Download
  • Crossref
Original Articles
Increased Cerebrovascular Resistance in Liver Cirrhosis and Ascites
Seong Woo Jeon, M.D., Won Young Tak, M.D., Young Oh Kweon, M.D., Sung Kuk Kim, M.D., Yong Hwan Choi, M.D., Jun Mo Chung, M.D., Eung Ju Lee, M.D.,* Jong Yeol Kim, M.D.,* Hun Kyu Ryeom, M.D.‡
Korean J Hepatol 1999;5(1):33-42.
Background/Aims
: Portal hypertension in cirrhosis is associated with a hyperdynamic circulation, which is characterized by hypervolemia, high cardiac output, arterial hypotension and low peripheral vascular resistance. These circulatory abnormalities are thought to be secondary to a splanchnic arteriolar vasodilation related to the increase in portal pressure. Studies assessing regional hemodynamics in patients of cirrhosis with ascites have shown vasoconstriction in the renal circulation and in peripheral vascular territory. This study was designed to assess the cerebral vascular resistance in cirrhotic patients with ascites. Methods : The resistive index in the middle cerebral artery and in a renal interlobar artery were measured by Doppler ultrasonography in 12 cirrhotic subjects without ascites, 23 cirrhotic subjects with ascites, and 8 healthy subjects. The arterial blood pressure and plasma renin and norepinephrine concentration, which reflect the activity of the renin-angiotensin and sympathetic nervous systems respectively, were also measured. Results : The resistive index in the middle cerebral artery were significantly higher in cirrhotic patients with ascites (0.58 0.04, mean standard deviation) than in cirrhotic patients without ascites (0.53 0.02, P<0.01) and in control subjects (0.50 0.05, P<0.01). The resistive index in the middle cerebral artery showed direct correlation with renal resistive index (r = 0.52, P<0.01), plasma renin activity (r = 0.44, P<0.01) and norepinephrine (r = 0.33, P<0.05). The resistive index in the middle cerebral artery showed an inverse correlation with mean arterial pressure (r = -0.59, P<0.01). Conclusion : The results suggest that in patients of cirrhosis with ascites, independent of the amount of ascites, there is a cerebral vasoconstriction which is related with the arterial hypotension and the overactivity of vasoconstrictor systems. (Korean J Hepatol 1999;5:33-42)
  • 3,271 View
  • 13 Download
The Usefulness of Monitoring of Transtubular Potassium Gradient and Spot Urine [Na] / [K] Ratio in the Management of Cirrhotic Ascites
Young Seok Lim,Hyo Suk Lee,Jung Hwan Yoon,Jin Suk Han,Chung Yong Kim
Korean J Hepatol 2000;6(1):12-23.
Background/Aims
: Transtubular potassium gradient(TTKG) is known as the most accurate indicator of aldosterone activity. TTKG may be used to monitor the effectiveness of aldosterone antagonist which is prescribed generally for the management of cirrhotic ascites. Spot urine [Na]/[K] ratio may also be used for the same purpose. Methods: After measuring TTKG, spot urine [Na]/[K] ratio, and plasma aldosterone concentration in each of the 23 patients all who had cirrhotic ascites, 100 mg of spiron- olactone was prescribed to be taken daily for 5 days. When no diuretic response occurred and TTKG was more than 3.5 at the end of 5 days, the dose of spironolactone was increased by 100 mg/day at the interval of 5 days until TTKG decreased to below 3.5. Furosemide was added to the non-responders if their TTKG had dropped to below 3.5. Results : Basal plasma concentration of aldosterone was higher than upper normal limit in 13(57%) patients, and correlated with TTKG significantly(r=0.60, p=0.002). TTKG was calculated to be 3.5±0.67 when assuming the aldosterone activity has been completely blocked. Spot urine [Na]/[K] ratio had significant negative correlation with TTKG before and after the administration of spironolactone. In most patients, diuretic response appeared with the fall of TTKG (especially below 3.5) and with the rise of spot urine [Na]/[K] ratio. In patients who did not respond to a low dose spironolactone, further treatment plan (to increase dose of spironolactone or to add furosemide) was guided by TTKG, and all were successful. Conclusions : TTKG and spot urine [Na]/[K] ratio are good indicators of aldosterone activity, and might be used as useful guidelines in the diuretic management of cirrhotic ascites.(Korean J Hepatol 2000;6:12-23)
  • 3,724 View
  • 33 Download
The Significance of Urine Sodium Measurement after Furosemide Administration in Diuretics-unresponsive Patients with Liver Cirrhosis
Hyun Seok Cho, M.D., Geun Tae Park, M.D., Young Hoon Kim, M.D., Sung Gon Shim, M.D., Jin Bae Kim, M.D., Oh Young Lee, M.D., Ho Soon Choi, M.D., Joon Soo Hahm, M.D. and Min Ho Lee, M.D.
Korean J Hepatol 2003;9(4):324-331.
Background/Aims
The diagnosis of refractory ascites means a poor prognosis for patients with liver cirrhosis. The definition of refractory ascites has already been established, but using the dosage of diuretics that correlates with the definition of refractory ascites in an out-patient department will lower the compliance of the patient, as well as causing serious complications, such as hepatic encephalopathy and hyponatremia, as the dosage of diuretics is increased. Due to this fact, it is very difficult to apply this definition of refractory ascites to patients in a domestic out-patient department. In this study, in situations where there are difficulties in applying the diuretics dosage according to definition of refractory ascites, we tried to find out whether measuring the value of urine sodium after the administration of intravenous furosemide can be the standard in early differentiation of the response to diuretics treatment. Methods: We reviewed 16 cases of liver cirrhosis with ascites and classified them into two groups by the response to diuretics. The diuretics-responsive ascites group was 8 cases and the diuretics-unresponsive ascites group consisted of 8 cases. After admission, we examined the patients’ CBC, biochemical liver function test, spot urine sodium, and 24 hour creatinine clearance. After the beginning of the experiment, all diuretic therapy was stopped for 3 days. Daily we examined the patients’ CBC, biochemical liver function test, and in the 3rd experiment day, we measured 24-hour urine volume and sodium. In the 4th experiment day, after sampling for ADH, plasma renin activity and plasma aldosterone level, we administrated the furosemide 80 mg I.V, and measured the amount of 8 hour urine volume and sodium. Results: The plasma aldosterone level was significantly higher in the diuretics- unresponsive ascites group than in the diuretics-responsive ascites group. In the 4th experiment day, the amount of urine volume and sodium was very significantly lower in the diuretics-unresponsive ascites group than in the diuretics-responsive ascites group (1297.5±80.9 vs 2003.7±114.6 ml, p<0.005, 77.3±8.2 vs 211.8±12.6 mEq, p<0.001). Conclusions: In out-patient departments, the measurement of urine sodium 8 hours after administrating 80 mg of intravenous furosemide, will help in differentiating ascites patients with lower treatment response to diuretics.(Korean J Hepatol 2003;9:324-331)
  • 4,037 View
  • 60 Download
Changes of Ascites Nitric Oxide According to the Treatment Course in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
Young Soo Park, M.D., Chae Yoon Chon, M.D., Hyeyoung Kim, Ph.D.*, Yong Han Paik, M.D., Si Young Song, M.D., Sang Hoon Ahn, M.D., Sinae Hong , Kwang-Hyub Han, M.D. and Young Myoung Moon, M.D.
Korean J Hepatol 2004;10(3):207-215.
Background/Aims
Nitricoxide (NO) is a molecule involved in vascular dilatation and pathogen suppression. It also has immunologic and regulatory functions. Liver cirrhosis is characterized by an increased risk for bacterial infections, including spontaneous bacterial peritonitis (SBP). The role of NO in SBP which develops in cirrhosis has not been clearly established. The aim of this study was to investigate the role of NO in the pathogenesis of SBP and its clinical usefulness for prediction of disease prognosis. Methods: This study was designed to investigate the changes of ascites NO in the course of treatment. Nitricoxide metabolite (nitrites+nitrates [NO x]) was measured by chemilum inescence in 84 ascites samples obtained from 84 cirrhotic patients. Among them , the 38 patients with SBP were treated with cefotaxim e 2.0 g, q 12hr for 7 days. In 24 of SBP patients, ascites was obtained consecutively before treatment (day 0),during treatment (day 2),and after treatment (day 7). Results: Ascites NO levels in the patients w ith SBP (n=38; 82.3 14.4 μM ) were not different from those in patients with sterile ascites (n=46; 54.6 13.0 μM ). There was no significant change of NO levels in sequential ascites samples during antibiotic treatment. A scites NO level before treatment was significantly higher in SBP patients who responded to antibiotics (n=26; 101.86 μM/L) than that in SBP patients who did not respond to antibiotics (n=12; 40.03 μM/L, P =0.044). A significant direct correlation was found between ascites and serum NO levels before treatment (Pearson correlation,r2=0.86,P =0.001). Among the SBP patients, treatment response rate to antibiotics were significantly higher in those patients with pretreatment NO level≥80 μM/L in multivariate analysis. Conclusions: Ascites NO level was not different between ascites from SBP patients and ascites from cirrhotic patients with sterile ascites. There were no changes of ascites NO in SBP patients during treatment. Therefore ascites NO was not useful to predict the progress of SBP. Ascites NO levels reflect serum NO levels, and the patients with higher NO level may have better response to antibiotics. (Korean J Hepatol 2004;10:207-215)
  • 3,454 View
  • 14 Download
Usefulness of Reagent Strips for the Diagnosis of Spontaneous Bacterial Peritonitis
Dae Kyoum Kim , Dong Jin Suh , Gi Deog Kim , Won Beom Choi , Sung Hoon Kim , Young Suk Lim , Han Chu Lee , Yong Hwa Chung , Yung Sang Lee
Korean J Hepatol 2005;11(3):243-249.
Background/Aims
Spontaneous bacterial peritonitis (SBP) is one of the potentially life-threatening complications for patients with liver cirrhosis, and it has a mortality rate of over 20%. Early diagnosis of SBP and immediate use of an adequate antibiotic therapy are very important for achieving a better prognosis. The aim of our study was to assess the usefulness of reagent strips for making the rapid diagnosis of SBP. Methods: A diagnostic paracentesis procedure was performed upon hospital admission in 257 cirrhotic patients (187 males, 70 females; mean age: 54 years) with ascites. Each fresh sample of ascitic fluid was tested using a reagent strip, and the result was scored as 0, 1+, 2+ or 3+. The leukocyte count, polymorphonuclear cell count, blood bottle culture, and chemistry of ascites were also done. Results: We diagnosed 79 cases of SBP and 2 cases of secondary bacterial peritonitis by means of the polymorphonuclear cell count and the classical criteria. When a reagent strip result of 3+ was considered positive, the test`s sensitivity was 86% (70 of 81), the specificity was 100% (176 of 176), and the positive predictive value was 94%. Furthermore, when a reagent strip result of 2+ or more was considered positive, the test sensitivity was 100% (81 of 81), the specificity was 99% (174 of 176), and negative predictive value was 99%. Conclusions: The use of reagent strips is a very sensitive and specific tool for the rapid diagnosis of SBP in cirrhotic patients. A positive result should be an indication for empirical antibiotic therapy, and a negative result may be useful as a screening test to exclude SBP. (Korean J Hepatol 2005;11:243-249)
  • 3,396 View
  • 19 Download
Etiologic and Laboratory Analyses of Ascites in Patients who Underwent Diagnostic Paracentesis
Young Hwangbo , Ji Heon Jung , Jae Joon Shim , Byung Ho Kim , Sung Hoon Jung , Chang Kyun Lee , Jae Young Jang , Seok Ho Dong , Hyo Jong Kim , Young Woon Chang , Rin Chan
Korean J Hepatol 2007;13(2):185-195.
Background/Aims
Liver cirrhosis and malignant tumors are two major causes of ascites according to the reports from Western countries, 80% and 10% respectively. Assuming that there might be regional differences in etiologies and changes in their frequency over time, we investigated causes of ascites and the diagnostic usefulness of various laboratory tests. Methods: Medical records of 366 patients, who underwent diagnostic paracentesis in the mid-1990s (1996 and 1997) and early 2000s (2001 and 2002), were retrospectively reviewed. The etiology was confirmed by histology, imaging studies, and ascites analyses. Results: The frequency of cirrhotic ascites was 59.6%, cancer-related 25.7%, tuberculous peritonitis 6.6%, and others 8.1%. Among cirrhotics, the frequency of cases related to hepatitis B decreased significantly from 72% to 55% over time, and alcoholic cirrhosis increased from 18% to 34%. Among cancer-related ascites, peritoneal carcinomatosis type was 75.5% (primary sites: stomach 24.5%, pancreas 15.9%, colon 15.9%, lung 7.4%, etc), metastatic liver cancers 8.5%, hepatocellular carcinoma without cirrhosis 6.4%, etc. The sensitivity of serum-ascites albumin gradient for the diagnosis of cirrhotic ascites was 91.4%, and total protein in ascites also revealed a comparable diagnostic sensitivity, 90%. The diagnostic sensitivity of adenosine deaminase for tuberculous peritonitis was 94.2%, and its positive predictive value was 75%. Conclusions: Liver cirrhosis is the leading cause of ascites, especially alcoholic cirrhosis has significantly increased. The next common etiology is cancer-related, and its frequency in Korea is higher than in western countries. Tuberculous peritonitis is still prevalent, and adenosine deaminase could precisely differentiate it from other causes. (Korean J Hepatol 2007;13:185-195)
  • 4,203 View
  • 49 Download